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6ABSTRACT
To identify the genes involved in the process of thyroid carcinogenesis we
have analysed the gene expression profiles of six thyroid carcinoma cell lines
compared with normal human thyroid primary cell culture using an Affymetrix
HG_U95Av2 oligonucleotide array representing ~10.500 unique genes. This
study led to the identification of genes whose expression was up- or down-
regulated in the carcinoma cell lines compared with the primary cell culture of
normal thyroid origin.
We identified 510 up-regulated transcripts and 320 down-regulated transcripts
with a fold change higher than 10 in all of the carcinoma cell lines. In particular
our interest was focused on the genes whose expression was drastically (at least
10 fold) up- or down-regulated in all the cell lines, assuming that the genes altered
in their expression in all of the thyroid carcinoma cell lines might represent
candidate genes involved in thyroid cell transformation.
Among the down-regulated genes, we directed our attention to Chromobox
homolog 7 (CBX7) that resulted down-regulated about 20 fold in all the
carcinoma cell lines analysed.
 CBX7 is a chromobox family protein, probably involved in the compaction of
heterochromatin. Expression analyses performed using several techniques such as
RT-PCR and immunohistochemistry showed that the down-regulation of this gene
strongly correlated with the onset of a highly malignant phenotype of thyroid
carcinomas.
Thus, to better elucidate the function of CBX7 in carcinogenesis, we settled on
the identification of novel CBX7 biological partners.
7In the cells, many proteins display their biological functions through the rapid
and transient association within large protein complexes. The association of an
unknown protein with partners belonging to a specific protein complex involved
in a particular process could inform on its biological function. Furthermore, a
detailed description of the cellular signalling pathways might greatly benefit from
the elucidation of protein–protein interactions in the cell.
For this aim we have performed a proteomic assay that led us to the
identification of some interesting proteins that can modulate the activity of CBX7
to E-cadherin, an important mediator of the epithelial-mesenchymal transition
(EMT).
Loss of E-cadherin expression seems to be crucial involved in EMT, and E-
cadherin is therefore emerging as one of the caretakers of the epithelial
phenotype. Downregulation of E-cadherin (or mutations that occur in cancer) has
several important consequences that are of direct relevance to EMT.
The ability of CBX7 to positively regulate E-cadherin expression by
interacting with HDAC2 and inhibiting its activity on the E-cadherin promoter
would account for the correlation of the loss of CBX7 and E-cadherin expression
with a highly malignant phenotype in thyroid cancer patients.
We have also identified another protein, Metastasis associated protein 3
(MTA3) that interact with CBX7 and could regulate E-cadherin expression, as
already described in breast cancer.
Finally, another pathway that might be important in the regulation of activity of
CBX7 is the arginine methylation by PRMT1 and PRMT5.
8Thus, the many important interacting proteins of CBX7 and the pathways in
which they are involved strongly suggest that CBX7 can be considerated a very
important regulator of thyroid malignant transformation.
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1.1 The thyroid gland
The thyroid gland is the largest endocrine organ in humans (1). It is
located in the neck region, on the anterior surface of the trachea, and is formed by
two distinct cell types, the follicular cells (TFC) and the parafollicular or C cells
(2). The TFC constitute the most numerous cell population and form the thyroid
follicles, spherical structures that store and release the thyroid hormones (3). The
C cells are located between follicles, mostly in a parafollicular position (Figure 1).
Figure 1 The general architecture of the thyroid gland
Figure shows the general architecture of the thyroid gland with the parafollicular cells,
interspersed in small groups among the follicles in the intermediate part of the thyroid lobes.
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These two cell types take origin from two different embryological
structures: the thyroid anlage for the TFC and the ultimobranchial bodies for the C
cells. The thyroid anlage is an area enclosing a small group of endodermal cells,
and it is located on the midline of the embryonic mouth cavity in its posterior part.
The ultimobranchial bodies are a pair of transient embryonic structures
derived from the fourth pharyngeal pouch and located symmetrically on the sides
of the developing neck: C cell precursors migrate from the neural crest (4) in these
structures (5). The cells of the thyroid anlage and the ultimobranchial bodies
migrate from their respective sites of origin and ultimately merge in the definitive
thyroid gland. Once merged, the thyroid anlage and the ultimobranchial bodies
disappear and their cells disperse in the adult thyroid gland. At this point the cells
from the anlage continue to organize the thyroid follicles, whereas the C cells
scatter within the interfollicular space. Interestingly, in some animals the
ultimobranchial structures remain distinct from the rest of the thyroid gland (6).
In the adult human, the gland has a butterfly shape and has a weight of
15–25 g. It is comprised of aggregates (lobules) of spherical follicles that are
filled with colloid. The follicles range in size from 50–500 µm and are lined by
cuboidal-to-flat follicular epithelial cells. The main functions of the thyroid gland
are synthesis, storage and secretion of thyroid hormones, L-triiodothyronine (T3)
and L-thyroxine (T4) (1). This mechanism is under the control of the
hypothalamic-pituitary axis with negative feedback by the thyroid hormones:
thyrotropin releasing hormone (TRH), secreted from the hypothalamus, stimulates
the release of thyroid-stimulating hormone (TSH) from the anterior pituitary
gland. TSH, then, is able to stimulate the follicular cells to synthesize and secrete
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thyroid hormones. Disruption of thyroid hormone homeostasis results in
hypothyroidism, goiter and in childhood cretinism (1).
The parafollicular C-cells secrete calcitonin, which is important for the
bone formation. Its secretion is stimulated by elevate calcium concentration in the
serum (7,8).
1.2 Thyroid follicular cell carcinomas
Thyroid carcinomas that originates from TFC are mainly divided into
well-differentiated, poorly differentiated and undifferentiated carcinomas on the
basis of clinico-pathological parameters such as prevalence, sex ratio, age,
local/distant metastasis and survival rate (1). Papillary (PTC) and follicular (FTC)
thyroid carcinomas are considered well-differentiated carcinomas (Kondo et al.
2006). Although initially defined by architectural criteria, the histological
diagnosis of PTC rests on a number of nuclear features that predict the propensity
for metastasis to local lymph nodes (9). The diagnosis of this most frequent type
of thyroid malignancy (85–90% of thyroid malignancies) has been increasing,
possibly owing to the changing recognition of nuclear morphological criteria. On
the other hand, FTC is characterized by haematogenous spread, and the frequency
of its diagnosis has been decreasing (10). Most well-differentiated thyroid cancers
behave in an indolent manner and have an good prognosis. By contrast, anaplastic
(ATC) thyroid carcinoma (undifferentiated) is highly aggressive and always fatal
(9, 11). For this type of cancer there is not an effective treatment and, monstly, the
prognosis is poor and death occurs within one year from the diagnosis. Finally,
poorly differentiated (PDC) thyroid carcinomas are intermediate forms between
12
well-differentiated and undifferentiated, morphologically and behaviourally (9,12,
13).
Thyroid neoplasms, therefore, represent a good model for studying the
events involved in epithelial cell multistep carcinogenesis (Figure 2), because they
comprise a broad spectrum of lesions with different degrees of malignancy from
benign adenomas (FA) (not invasive and very well differentiated) to the ATC
(very aggressive and always fatal), with the intermediate forms represented by
PTC and FTC (differentiated and with a good prognosis) (1, 14, 15).
Figure 2 Model of multi-step carcinogenesis of thyroid neoplasms
On the basis of clinical, histological and molecular observations, three distinct pathways are
proposed for neoplastic proliferation of thyroid follicular cells, including hyper-functioning
follicular thyroid adenoma (tumours that are almost always benign lesions without a propensity for
progression), follicular thyroid carcinoma and papillary thyroid carcinoma. Genetic defects that
result in activation of RET or BRAF represent early, frequent initiating events that can be
associated with radiation exposure. Most poorly differentiated and undifferentiated thyroid
carcinomas are considered to derive from pre-existing well-differentiated thyroid carcinomas
through additional genetic events, including p53 inactivation, but de novo occurrence might also
occur.
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Point mutations, rearrangements that activate proto-oncogenes, and loss-
of-function in tumor suppressor genes have been identified in thyroid tumors (1).
The involvement of several oncogenes has been demonstrated in PTC: activation
of the RET/PTC oncogene, caused by rearrangements of the RET proto-oncogene,
occurs in about 30% of cases (1), whereas the B-RAF gene is mutated in about
40% of cases (16). These tumors have also been associated with TRK gene
rearrangements (17) and MET gene overexpression (18). RAS gene mutations
(19) and PAX8-PPAR-! rearrangements (20) are frequent in FTC, whereas
impaired function of the p53 tumor suppressor gene is typical of ATC (21-23).
Other genes have been implicated in thyroid neoplasias. Even though critical
molecular mechanisms of thyroid carcinogenesis have been clarified, other
molecular steps of neoplastic progression need to be investigated.
1.3 Microarray analysis of human carcinomas
DNA microarray technology was introduced in the scientific community in
the mid-1990s to check the expression levels of thousands of genes
simultaneously (24, 25). This kind of analysis was quickly adopted by the
research community for the study of a wide range of biologic processes. Most of
the early studies were performed simply to compare two biologic classes in order
to identify the difference in gene expression, particularly of genes with potential
relevance to a wide range of biological processes, such as the progression of
cancer (26-29), the causes of asthma (30-32), heart diseases (33-35),
neuropsychiatric disorders (36-38), and the analysis of factors associated with
infertility (38-39).
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Soon after its introduction, microarray technology was used to find new
subclasses in disease states (40-41) and to identify biomarkers associated with
disease (42), establishing that gene expression patterns could be used to
distinguish subclasses of disease (28, 43-45).
This concept resulted in a proliferation of searches for patterns of
expression that could be used to classify types of tumors (46) and to predict their
outcome (47-48) and the response to therapy (48-49). In fact, gene expression
profiling studies based upon this new technology has been successfully used to
discover consistent gene expression patterns associated with a histological or
clinical phenotype (48, 50-56) and also to predict the clinical outcome and
survival as well as to classify different types of cancer (47, 48, 54-57). The
research focus has now shifted toward identifying genetic determinants that are
components of the specific regulatory pathways altered in cancers, leading to the
discovery of novel therapeutic targets. In this view, our group, recently,
investigated the Ras-dependent modulation of gene expression in thyroid cells
(58). However, it is not easy to select few candidate genes for further studies from
the lengthy gene lists generated from gene expression profiling studies (59). This
approach, however, promises to provide diagnostic and prognostic markers that
can be clinically used in the near future (60).
Therefore, to identify candidate genes involved in the process of thyroid
carcinogenesis, we analysed a microarray, that represents 12.625 sequences, with
RNAs extracted from normal human thyroid primary cell culture (NTPC), and six
human thyroid carcinoma cell lines of different histotype (1 from a follicular
carcinoma, 3 derived from papillary carcinomas and 2 from anaplastic
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carcinomas). We focused our interest on the genes whose expression was
drastically (at least 10 fold) up- or down-regulated in all of the six thyroid
carcinoma cell lines in comparison to the normal thyroid primary cell culture
assuming that the genes altered in their expression in all of the thyroid carcinoma
cell lines might represent candidate genes involved in thyroid cell transformation.
1.4 CBX7 and Polycomb group genes
Within the context of this microarray study, we found that the CBX7
(Chromobox homolog 7) gene was down-regulated in the thyroid carcinoma-
derived cell lines and also in thyroid fresh tumors. CBX7 encodes a novel protein
that is a part of the Polycomb Group protein (61).
Polycomb Group genes (PcG) are a set of genes linking histone
modifications with transcriptional repression: they are structurally diverse but
functionally epistatic (62, 63). PcG proteins are part of two complexes with high
molecular weight called Polycomb repressive complexes 1 and 2, PRC1 and
PRC2 (Figure 3). (63, 64).
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Figure 3 Mechanism of transcriptional repression by Polycomb Group proteins
The binding of Polycomb repressive complex 2 (PRC2) to Polycomb responsive elements (PRE)
triggers histone deacetylation, and methylation of lysine 27 in Histone H3, both around the PRE
and in the promoter region of the genes silenced. This modification constitutes one of the signals
for the recruitment of the Polycomb repressive complex 1 (PRC1), or maintenance complex,
which represses gene expression by inhibiting transcription initiation (Gil et al. 2005).
The PRC1 complex can recognize and bind to trimethylated K27 of
Histone H3 through Polycomb proteins, and contributes to gene repression by
inhibiting transcription initiation (65). The components of the core of this
complex in mammals are the homologs of Drosophila Polycomb (Pc), Posterior
sex combs (Psc), Sex combs extra (Sce) and Polyhomeiotic (Ph). The PRC2
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complex, instead, has associated histone deacetylase and histone methyl
transferase (specific for lysine of Histone H3, K27H3) activities; thus, it
contributes to establish an histone repressive marks (66, 67). Among the known
mammalian components of this second complex are Enhancer of Zeste (EZH2),
Early embryonic deficient (EED), Suppressor of Zeste (SUZ12) and other
associated proteins.
It is well known that PcG proteins deregulation is involved in
tumorigenesis. In fact several studies have demonstrated that, for example, Bmi-1
is amplified in blood malignancies and medulloblastomas (68-71); EZH2 is
involved in blood malignancies (68, 72), being its expression increased in prostate
and breast tumors metastasis (73, 74); Mel18 has been suggested to act as a tumor
suppressor gene (75); Rae28/Ph1 alterations are observed in acute lymphoblastic
leukemia (76) and SUZ12 is up-regulated in colon tumors (77). Evidence is
rapidly increasing that PcG genes are a novel class of oncogenes and anti-
oncogenes, which may in future years become central to the development of novel
cancer therapies based on epigenetic gene silencing (78, 79). Not only PcG genes
such as BMI-1 and EZH2 are capable of cellular transformation, but also they are
vital for cell survival. To date, abnormal PcG genes expression has been described
in most human cancers. Also, the correlation between PcG expression and
biological behavior of clinically defined cancer subtypes suggests that these genes
play a central role in oncogenesis, and holds a promise for discovery of novel
diagnostic markers (80).
CBX7 and the others PcG proteins contain a chromodomain in the N-
terminus (CBX7 between amino acids 10 and 46). This domain was originally
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identified in Drosophila melanogaster as a 37-amino-acid region of homology
shared by heterochromatin protein 1 (HP1) and Polycomb (Pc) proteins (81).
Phylogenetic and sequence analyses of the chromodomain (Figure 4A and B)
revealed that CBX7 has a great similarity to other known or putative Pc proteins
like CBX2 (Pc1), CBX4 (Pc2), CBX6 and CBX8 (Pc3). This similarity is less
pronounced respect to the HP1 proteins, such as CBX1 (HP1"), CBX3 (HP1!),
CBX5 (HP1#) and, moreover, CBX7 does not contain the “chromo-shadow
domain” that, instead, is a hallmark of HP1 proteins. CBX7 protein contains also
other specific conserved residues that distinguish Pc and HP1 chromodomains:
these residues specific of the Pc proteins are necessary both for Pc dimerization
and recognition of tri-methylated Lys 27 on histone H3 (82).
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Figure 4 CBX7 and chromodomain
Identification of CBX7 as a Polycomb protein. (A) Phylogenetic analysis of Chromobox (CBX)
proteins. Lines grouped by open rectangles denote orthologs of a same CBX protein (name in the
right). Full rectangles refer to proteins that cannot be considered purely orthologs of any of the
CBX proteins. Pc proteins are shown in blue, and HP1 proteins in red. CBX7 and CBX6 are
shown in black. (B) Alignment of CBX7 chromodomain with that of other known and putative
human Polycombs. Identical residues are shown in a yellow background, and similar residues are
shown in a cyan background. (C) Alignment of CBX7 Polycomb box with that of other known and
putative human Polycombs. Background colours are as described in (B) (from Gil et al. 2004).
In addition to the high homology within the chromodomain, CBX7 has
also homology to Pc proteins in a carboxy-terminal region (Figure 4C) previously
defined as the Pc box or C-box (83). It is known that the Pc box (amino acids
231–243) and the chromodomain (83) are both necessary for CBX7 function. It
was seen that a fusion protein between CBX7 and the DNA-binding domain of
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Gal4 is able to repress, in a dose dependent manner, the transcription over a
4xGal4-tk-luc reporter, suggesting that CBX7 functions by repressing
transcription (61). So, CBX7 seems to act like the others Pc proteins exerting its
effect through transcriptional repression.
Mouse CBX7 is, moreover, able to associate with facultative
heterochromatin and with the inactive X chromosome, which indicates that CBX7
is really involved in the repression of gene transcription (84). CBX7 is also
capable to interact with different Pc group members. In fact, similarly to other Pc
proteins, CBX7 is able to inter-functions with itself and with the ring-finger
protein Ring1 (61), as reported by Glutathione S-transferase (GST) pull-down
experiments (85, 86). In addition, within the nucleus, CBX7 co-localizes with
Ring1 to distinct foci-like structures termed Pc-bodies (87), in several cell lines,
as demonstrated with immunofluorescence microscopy studies. However, there is
not association between CBX7 and other PcG proteins, such as Bmi1, EED or
EHZ2 (61) suggesting that CBX7 is part of different complexes than Bmi1 and
Pc2.
Mouse CBX7 displays strong affinity for both H3K9me3 and H3K27me3
and is developmentally regulated in its association with chromatin(84). It has also
been demostrated that chromodomain of CBX7 is essential for the binding to
H3K9me3 and H3K27me3, in some cases associated with repressive state.
It has also been found that, in vitro, the chromodomain of CBX7 can bind
RNA and that, in vivo, the interaction of CBX7 with chromatin, and the inactive X
chromosome in particular, partly depends on its association with RNA (84). These
data suggest that the capacity of this mouse Polycomb homolog to associate with
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the inactive X chromosome, or any other region of chromatin, depends not only
on its chromodomain but also on the combination of histone modifications and
RNA molecules present at its target sites (84).
CBX7 is highly expressed in several tissues, including brain, kidney, heart
and skeletal muscle. (61). A recent study has demonstrated that CBX7 expression
is associated with extension of cellular life span in mouse embryonic fibroblasts
and human prostate primary epithelial cells by downregulating expression of the
Ink4a/Arf locus (61, 88). However, another study on ependymoma (89) reported a
consistent down-regulation of CBX7 in the tumor samples, with the loss of at
least one copy of the gene in 55% of the cases examined. This study also
proposed other mechanisms than CBX7/p16 pathway, since in ependymoma,
although gene mutations are rare, hypermethylation of p16Ink4a, Rb and p14ARF
has been reported in a subgroup of tumors (4%–32%) (89).
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1.5 Epithelial–mesenchymal transition
Epithelial–mesenchymal transition is an indispensable mechanism during
morphogenesis which allows tissues and organs formation (90). Epithelial and
mesenchymal cells differ in various functional and phenotypic characteristics.
Epithelial cells grow in layers and communicate through specialized membrane
structures, such as tight junctions, adherens junctions, desmosomes and gap
junctions. Epithelial cells are motile and can move away from their nearest
neighbours, while remaining within the epithelial layer (91). Mesenchymal cells,
on the other hand, do not form an organized cell layer, nor do they have the same
apical–basolateral organization and polarization of the cell-surface molecules and
the actin cytoskeleton as epithelial cells.
Epithelial cells can convert into mesenchymal cells by a process known as
the epithelial–mesenchymal transition. The term EMT describes a series of events
during which epithelial cells loose many of their epithelial characteristics and take
on properties that are typical of mesenchymal cells, which require complex
changes in cell architecture and behaviour. The precise spectrum of changes that
occur during EMT is probably determined by the integration of extracellular
signals the cell receives, although this is still unclear.
The reverse process, known as mesenchymal–epithelial transition (MET),
has also been reported, as shown in figure 5 (92-95).
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Figure 5 The cycle of epithelial-cell plasticity
The diagram shows the cycle of events during which epithelial cells are transformed into
mesenchymal cells and vice versa. The different stages during EMT (epithelial–mesenchymal
transition) and the reverse process MET (mesenchymal–epithelial transition) are regulated by
effectors of EMT and MET, which influence each other. Important events during the progression
of EMT and MET, including the regulation of the tight junctions and the adherens junctions, are
indicated.
Without epithelial–mesenchymal transitions, in which polarized epithelial
cells are converted into motile cells, multicellular organisms would be incapable
of getting past the blastula stage of embryonic development (96). However, this
important developmental programme has a more sinister role in tumour
progression. Epithelial–mesenchymal transition provides a new basis for
understanding cancer progression towards dedifferentiated and more malignant
states (Figure 6).
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Figure 6 Sites of EMT and MET in the emergence and progression of carcinoma
 Normal epithelia lined by a basement membrane can proliferate locally to give rise to an
adenoma. Further transformation by epigenetic changes and genetic alterations leads to a
carcinoma in situ, still outlined by an intact basement membrane. Further alterations can induce
local dissemination of carcinoma cells, possibly through an epithelial—mesenchymal transition
(EMT), and the basement membrane becomes fragmented. The cells can intravasate into lymph or
blood vessels, allowing their passive transport to distant organs. At secondary sites, solitary
carcinoma cells can extravasate and either remain solitary (micrometastasis) or they can form a
new carcinoma through a mesenchymal—epithelial transition (MET).
Studies show that several extracellular activators can trigger EMT, that
extensive crosstalk exists between the signalling pathways that activate and
repress EMT, and that EMT-inducing signalling pathways have many common
endpoints, including downregulation of E-cadherin expression and expression of
EMT-associated genes (90).
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Many effectors orchestrate the disassembly of junctional complexes and
the changes in cytoskeletal organization that occur during EMT. The activation of
signalling pathways also results in the activation of transcriptional regulators such
as snail (now known as SNAI1)(97) and slug (now known as SNAI2), which
regulate the changes in gene-expression patterns that underlie EMT.
A central target of these transcriptional regulators is the repression of the
E-cadherin gene, an important caretaker of the epithelial phenotype.
Downregulation of E-cadherin (or mutations that occur in cancer) has several
important consequences that are of direct relevance to EMT. E-cadherin levels
become limiting, which results in the loss of E-cadherin-dependent intercellular
epithelial junctional complexes, and E-cadherin-mediated sequestering of "-
catenin in the cytoplasm is abolished, as shown in figure 7 (90).
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Figure 7 Overview of the molecular networks that regulate EMT
A selection of the signalling pathways that are activated by regulators of EMT and a limited
representation of their crosstalk is illustrated. Activation of receptor tyrosine kinases (RTKs) is
known to induce EMT in several epithelial cell types and in vivo, but it is now clear that the EMT
process often requires co-activation of integrin receptors. The role of transforming growth factor-"
(TGF) signalling in EMT is established for a limited number of normal and transformed cell lines,
whereas in vivo data has indicated a mutual regulation of the TGF and NOTCH pathways during
EMT. There is now increasing evidence that other signalling pathways could have an important
role in EMT, including those elicited by G-protein-coupled receptors. Matrix metalloproteinases
(MMPs) can also trigger EMT through as-yet-undefined receptors.
It took a long time for EMT to be recognized as a potential mechanism for
carcinoma progression (96).
During progression to metastatic competence, carcinoma cells acquire
mesenchymal gene-expression patterns and properties. This results in changed
adhesive properties, and the activation of proteolysis and motility, which allows
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the tumour cells to metastasize and establish secondary tumours at distant sites
(98). In tissue culture this progression is accompanied by partial or complete
EMT, and induction of EMT in many carcinoma cell lines results in the
acquisition of metastatic properties in vivo. Infact, it is striking that the same
signalling pathways that regulate developmental EMT are also activated during
tumour progression.
Local invasion can be considered an initial and essential step in the
malignancy of carcinomas, leading to the generation of usually fatal distant
metastasis. Tumour invasion appears to be controlled by a coordinated series of
cellular and molecular processes that enable tumour cells to dissociate and
migrate from the primary tumor.
One of the hallmarks of EMT is the functional loss of E-cadherin (encoded
by CDH1), which is currently thought to be a suppressor of invasion during
carcinoma progression (96).
E-cadherin is therefore emerging as one of the caretakers of the epithelial
phenotype. E-cadherin is the prototypic type I cadherin. Type I cadherins mediate
homophilic interactions by forming adhesive bonds between one or several
immunoglobulin (Ig) domains in their extracellular region and connecting to actin
microfilaments indirectly via #-catenin and "-catenin in the cytoplasm.
So how is E-cadherin downregulated? In most cases, downregulation
during carcinoma progression occurs by epigenetic mechanisms, including
transcriptional repression and promoter hypermethylation. Occasionally, the E-
cadherin gene is mutated, leading to the absence or to the expression of a non-
functional protein(99-106).
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1.6 E-cadherin
The cadherin superfamily of Ca2+-dependent homophilic adhesion
molecules plays a critical role in regulating cell-to-cell interactions. Alterations in
cadherin expression or function occur frequently during carcinogenesis, such as
the loss of the epithelial cadherin (E-cadherin) and/or the aberrant expression of
other cadherins. Indeed, the aberrant expression of cadherins has been detected
during carcinoma invasion, a process which is reminiscent of the epithelial-
mesenchymal transition (EMT) so important in many critical developmental
processes.
The different cadherins constitute a superfamily of transmembrane
receptors that mediate Ca2+-dependent cell-to-cell homophilic interactions. In this
way, 5 different sub-families can be considered (Figure 8): 1) Classical cadherins
(type I), mainly localised to adherens junctions; 2) Highly related type II
cadherins; 3) Desmosomal cadherins (desmocollins and desmogleins) that form
desmosomal junctions; 4) Protocadherins, mainly implicated in neural
development; 5) Cadherin-related proteins, like the Flamingo and Fat-like
cadherins (107).
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Figure 8 Organization of the cadherin superfamily
The main structural and functional characteristics of the cadherin subfamilies and types are
indicated. Representative examples are shown, with gene denomination of some of them in
brackets. The main structural domains and schematic structure of the different cadherin types are
shown at the right.
Expression of E-cadherin is maintained in all epithelial tissues, but it is
silenced during the process of EMT and in established mesenchymal cells (108,
109).
During the last decade, the expression of cadherins during tumour
progression has been the subject of extensive studies, the majority of which have
focused on the role of E-cadherin. The loss of E-cadherin expression and/or
function has been observed during tumour progression of most carcinomas (110,
111), and this has been related to the induction of EMT which frequently occurs
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during carcinoma invasion (96, 112). E-cadherin can be considered as an invasion
suppressor gene (111).
Mechanisms of E-cadherin regulation during tumor progression
Most of our current knowledge regarding the way in which cadherin
expression is controlled during tumour progression has derived from studies on E-
cadherin. Indeed, the involvement of Ecadherin in epithelial morphogenesis and
homeostasis, and its proven anti-invasive role in carcinoma progression has
fomented interest in understanding the regulatory mechanisms that control E-
cadherin expression under normal and pathological circumstances.
The human E-cadherin gene (CDH1) is located at the 16q22.1 locus and is
comprised of 16 exons, spanning 99 Kb of genomic DNA. The mouse E-cadherin
gene (cdh1) has a similar exon-intron organisation and is located on chromosome
8. Loss of E-cadherin function is thought to be one of the most important events
during carcinoma progression (111), an assumption that is reinforced by the fact
that germ line mutations in CDH1 induce a predisposition to diffuse-type gastric
cancer (113). During tumour progression, E-cadherin can be functionally
inactivated by different mechanisms, including somatic mutation and down-
regulation of gene expression through promoter methylation and/or transcriptional
repression. Indeed, down-regulation of the CDH1 gene expression is observed in
many carcinomas (111), while inactivating mutations, frequent in diffuse gastric
carcinomas and in lobular breast carcinomas, are rarely observed in other types of
tumours (113, 114). Indeed, the most frequent genetic alterations of CDH1 in
tumours involve exon-skipping and out-of-frame mutations, and in most cases
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mutations occur in combination with a loss of heterozygosity of the wild type
allele (114).
Epigenetic mechanisms of E-cadherin silencing
The hypermethylation of CpG islands is associated with the recruitment of
methyl DNA binding proteins (MBDs) and of histone deacetylase activity
(HDACs), which together contribute to the compaction of the DNA in the
promoter region and hence, to gene inactivation. Of particular interest was the
finding that in diffuse-type gastric cancer, methylation of the E-cadherin promoter
serves as a second hit to somatic or germ-line genetic alterations in inactivating E-
cadherin expression (115). Indeed, it has also been proposed that methylation of E
cadherin CpG islands can act as a second hit for transcriptional expression to
silence E-cadherin in ductal breast carcinoma (116).
On the other hand, methylation of the E-cadherin promoter is not always
correlated with E-cadherin silencing (113), indicating that additional genetic or
epigenetic modifications might be required for E-cadherin down-regulation. The
molecular mechanisms involved in regulating E-cadherin methylation are starting
to be unravelled. Recently, the association of several MBDs, such as MeCP2,
MBD1 and MBD2, with the E-cadherin promoter have been reported in several
cancer cell lines (117). Interestingly, methylation of E-cadherin CpG islands and
MeCP2 expression have been shown to cooperatively and epigenetically regulate
E-cadherin expression in colorectal cancer cells (118). It is also possible t !h !a !t ! !o !t !h !e !r !
!e !p !i !g !e !n !e !t !i !c ! !m !e !c !h !a !n !i !s !m !s !, ! !l !i !k !e ! !h !i !s !t !o !n !e ! !d !e !a !c !e !t !y !l !a !t !i !o !n !, ! !p !a !r !t !i !c !i !p !a !t !e ! !i !n ! !r !e !g !u !l !a !t !i !n !g ! !E !-
!c !a !d !h !e !r !i !n ! !e !x !p !r !e !s !s !i !o !n !. ! !H !i !s !t !o !n !e ! !H !3 ! !d !e !a !c !e !t !y !l !a !t !i !o !n ! !i !s ! !a !s !s !o !c !i !a !t !e !d ! !w !i !t !h ! !C !p !G !
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!m !e !t !h !y !l !a !t !i !o !n !- !m !e !d !i !a !t !e !d ! !g !e !n !e ! !s !i !l !e !n !c !i !n !g ! !i !n ! !o !t !h !e !r ! !c !o !n !t !e !x !t !s ! !a !n !d ! !r !e !c !e !n !t !l !y !, ! !t !h !e !
!p !a !r !t !i !c !i !p !a !t !i !o !n ! !o !f ! !b !o !t !h ! !e !p !i !g !e !n !e !t !i !c ! !m !o !d !i !f !i !c !a !t !i !o !n !s ! !w !a !s ! !r !e !p !o !r !t !e !d ! !f !o !r ! !E !- !c !a !d !h !e !r !i !n ! !d !o !w !n !-
!r!e!g!u!l!a!t!i!o!n! !i!n! !s !e!v!e!r!a!l! !c!a!n!c!e!r! !c!e!l!l! !l!i!n!e!s ! !(!117!)!.!
!T!r!a!n !s !c!r!i!p !t!i!o!n !a!l! !r!e!g!u !l!a!t!i!o!n ! !o!f! !E!-!c!a!d !h !e!r!i!n ! !s !i!l!e!n !c!i!n !g
! B !e !s !i !d !e !s ! !r !e !g !u !l !a !t !i !o !n ! !o !f ! !E !- !c !a !d !h !e !r !i !n ! !b !y ! !p !r !o !m !o !t !e !r ! !h !y !p !e !r !m !e !t !h !y !l !a !t !i !o !n ! !a !n !d !/ !o !r !
!g !e !n !e !t !i !c ! !a !l !t !e !r !a !t !i !o !n !s !, ! !d !i !r !e !c !t ! !t !r !a !n !s !c !r !i !p !t !i !o !n !a !l ! !c !o !n !t !r !o !l ! !o !f ! !E !- !c !a !d !h !e !r !i !n ! !h !a !s ! !e !m !e !r !g !e !d ! !i !n ! !t !h !e !
!l!a!s !t! !y!e!a!r!s ! !a!s ! !a!n! !i!m!p!o!r!t!a!n!t! !r!e!g!u!l!a!t!o!r!y! !m!e!c!h!a!n!i!s !m! !o!f! !E!-!c!a!d!h!e!r!i!n! !e!x!p!r!e!s !s !i!o!n!.
!! T !h !e ! !m !o !u !s !e ! !E !- !c !a !d !h !e !r !i !n ! !p !r !o !m !o !t !e !r ! !w !a !s ! !f !i !r !s !t ! !i !s !o !l !a !t !e !d ! !i !n ! !1 !9 !9 !1 !. ! !I !t !s ! !i !n !i !t !i !a !l !
!c !h !a !r !a !c !t !e !r !i !za !t !i !o !n ! !s !h !o !w !e !d ! !that i !t ! !w !a !s ! !a ! !T !A !T !A !- !l !e !s !s ! !p !r !o !m !o !t !e !r ! !c !o !n !t !a !i !n !i !n !g ! !s !e !v !e !r !a !l !
!p !o !t !e !n !t !i !a !l ! !p !r !o !x !i !m !a !l ! !r !e !g !u !l !a !t !o !r !y ! !e !l !e !m !e !n !t !s !, ! !i !n !c !l !u !d !i !n !g ! !a ! !C !C !A !A !T ! !b !o !x ! !( !- !6 !5 !) !, ! !a ! !G !C !- !r !i !c !h !
!r !e !g !i !o !n ! !( !-3 !0 ! !t !o ! !- !5 !8 !) ! !a !n !d ! !a ! !p !a !l !i !n !d !r !o !m !i !c ! !e !l !e !m !e !n !t ! !( !- !7 !0 ! !t !o ! - !9 !0 !) ! !c !o !m !p !o !s !e !d ! !o !f ! !t !w !o !
!a !d !j !a !c !e !n !t ! !E !- !b !o !x !e !s ! !f !l !a !n !k !e !d ! !b !y ! !f !o !u !r ! !i !n !v !e !r !t !e !d ! !n !u !c !l !e !o !t !i !d !e !s ! !c !a !l !l !e !d ! E- !p !a !l ! !( !120 !) !. ! !T !h !e !
!p !r !o !x !i !m !a !l ! !C !C !A !A !T ! !a !n !d ! !G !C !- !r !i !c !h ! !r !e !g !i !o !n !s ! !a !r !e ! !r !e !q !u !i !r !e !d ! !f !o !r ! !b !a !s !a !l ! !E !- !c !a !d !h !e !r !i !n !
!e !x !p !r !e !s !s !i !o !n ! !a !n !d ! !a !r !e ! !r !e !c !o !g !n !i !z !e !d ! !b !y ! !c !o !n !s !t !i !t !u !t !i !v !e ! !A !P !2 ! !a !n !d ! !S !p !1 ! !t !r !a !n !s !c !r !i !p !t !i !o !n ! !f !a !c !t !o !r !s !, !
!a !n !d ! !C !A !A !T !- !b !i !n !d !i !n !g ! !p !r !o !t !e !i !n !s !, ! !r !e !s !p !e !c !t !i !v !e !l !y ! !( !119, !103 !, 120 !) (figure 9) !. ! !T !h !e ! !E !- !p !a !l !
!e !l !e !m !e !n !t ! !w !a !s ! !i !n !i !t !i !a !l !l !y ! !d !e !s !c !r !i !b !e !d ! !a !s ! !a !n ! !e !p !i !t !h !e !l !i !a !l !- !s !p !e !c !i !f !i !c ! !r !e !g !u !l !a !t !o !r ! !( !119 !) !, ! !b !u !t !
!s !u!b!s !e!q!u!e!n!t! !s !t!u!d!i!e!s ! !s !h!o!w !e!d! !i!t! !t!o! !b!e! !a!n! !a!c!t!i!v!e! !r!e!p!r!e!s !s !o!r! !i!n! !E-!c!a!d!h!e!r!i!n! !d!e!f!i!c!i!e!n!t! !c!e!l!l!s !
!(!103, 120, 105!!)!.!
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Figure 9 Schematic representation of the E-cadherin promoter region and E-box sequences
in mouse, human and dog
(A) The E-cadherin promoter region is represented with its representative proximal control
elements in the proximal region (exerting either a positive or negative effect on E-cadherin
expression). The CAAT, GC and E-box1/E-box3 are conserved in all three promoters, while the E-
box 2 is only present in the mouse promoter region. An additional E-box (E-box 4) downstream of
the transcription initiation site is present in the human promoter, but is not conserved in the region
encompassing the mouse promoter. Binding of identified factors to the different E-boxes is shown
in the lower part. (B) Sequence of the E-boxes present in the proximal region of the mouse, human
and dog E-cadherin promoter. Observe the high degree of conservation of E-box 1 and E-box 3.
S !e !v !e !r !a !l ! !s !t !u !d !i !e !s ! !h !a !v !e ! !d !e !m !o !n !s !t !r !a !t !e !d ! !t !h !a !t ! !t !h !e ! !E !- !b !o !x !e !s ! !i !n ! !t !h !e ! !p !r !o !x !i !m !a !l ! !E !-
!c !a !d !h !e !r !i !n ! !p !r !o !m !o !t !e !r ! !r !e !p !r !e !s !s ! !i !t !s ! !e !x !p !r !e !s !s !i !o !n !. ! !P !o !i !n !t ! !m !u !t !a !t !i !o !n !s ! !a !b !o !l !i !s !h !i !n !g ! !t !h !e ! !t !w !o ! !E !-
!b !o !x !e !s ! !i !n ! !t !h !e ! !m !o !u !s !e ! !E !- !p !a !l !, ! !o !r ! !E !- !b !o !x ! !1 ! !a !n !d ! !3 ! !i !n ! !t !h !e ! !h !u !m !a !n ! !p !r !o !m !o !t !e !r !, ! !p !r !o !d !u !c !e !d ! !a !
!s !t !r !o !n !g ! !i !n !d !u !c !t !i !o !n ! !o !f ! !E !- !c !a !d !h !e !r !i !n ! !p !r !o !m !o !t !e !r ! !a !c !t !i !v !i !t !y ! !i !n ! !d !i !f !f !e !r !e !n !t ! !c !a !r !c !i !n !o !m !a ! !c !e !l !l ! !l !i !n !e !s !
!d !e !f !i !c !i !e !n !t ! !i !n ! !E- !c !a !d !h !e !r !i !n ! !e !x !p !r !e !s !s !i !o !n !. ! E !v !i !d !e !n !c !e ! !h !a !s ! !a !l !s !o ! !b !e !e !n ! !p !r !e !s !e !n !t !e !d ! !t !h !a !t ! !t !h !e ! !E !-
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b !o !x ! !4 ! !a !l !s !o ! !r !e !p !r !e !s !s !e !s ! !E !- !c !a !d !h !e !r !i !n ! !e !x !p !r !e !s !s !i !o !n ! !( !121, 122 !) !, ! !h !e !n !c !e !, ! !f !a !c !t !o !r !s ! !a !b !l !e ! !t !o ! !b !i !n !d !
!t!o! !t!h!e! !E!-!b!o!x!e!s ! !a!n!d! !r!e!p!r!e!s !s ! !E!-!c!a!d!h!e!r!i!n! !e!x!p!r!e!s !s !i!o!n! !m!u!s !t! !b!e! !p!r!e!s !e!n!t! !i!n! !t!h!e!s !e! !c!e!l!l!s !.
C !h !a!r!a!c!t!e!r!i!za!t!i!o!n ! !o!f! !E!-!c!a!d !h !e!r!i!n ! !r!e!p !r!e!s !s !o!r!s
T !h !e ! !s !p !e !c !i !f !i !c !i !t !y ! !o !f ! !t !h !e ! !f !a !c !t !o !r !s ! !i !d !e !n !t !i !f !i !e !d ! !w !a !s ! !c !o !n !f !i !r !m !e !d ! !i !n ! !a ! !p !a !r !a !l !l !e !l ! !s !c !r !e !e !n !
!w !i !t !h ! !a !n ! !E !- !p !a !l ! !e !l !e !m !e !n !t ! !i !n ! !w !h !i !c !h ! !a ! !p !o !i !n !t ! !m !u !t !a !t !i !o !n ! !a !b !o !l !i !s !h !e !d ! !t !h !e ! !r !e !p !r !e !s !s !o !r ! !f !u !n !c !t !i !o !n !
!( !103, 120 !) ! !a !n !d ! !w !h !i !c !h ! !s !h !o !u !l !d ! !a !l !s !o ! !p !r !e !c !l !u !d !e ! !t !h !e ! !b !i !n !d !i !n !g ! !o !f ! !r !e !g !u !l !a !t !o !r !y ! !f !a !c !t !o !r !s !. ! !M !o !r !e !
!t !h !a !n ! !9 !0 !% ! !o !f ! !t !h !e ! !i !d !e !n !t !i !f !i !e !d ! !f !a !c !t !o !r !s ! !t !h !a !t ! !s !p !e !c !i !f !i !c !a !l !l !y ! !b !o !u !n !d ! !t !o ! !t !h !e ! !E !- !b !o !x !e !s !
!c !o !r !r !e !s !p !o !n !d !e !d ! !t !o ! !t !r !a !n !s !c !r !i !p !t !i !o !n ! !f !a !c !t !o !r !s !, ! !o !f ! !w !h !i !c !h !, ! !t !w !o ! !i !n ! !p !a !r !t !i !c !u !l !a !r ! !w !e !r !e ! !h !i !g !h !l !y !
!r !e!p !r !e!s !e!n !t!e!d !:! !4 !9 !% ! !c!o !r !r !e!s !p !o !n !d !e!d ! !t!o ! !t!h !e! !z!i!n !c! !f !i!n !g !e!r ! !f !a!c!t!o !r ! !S !n!a!i!l! !a!n !d ! !3 !2 !% ! !t!o ! !t!h !e! !c!l!a!s !s !
!I ! !b !H !L !H ! !f !a !c !t !o !r !s !, ! !E !4 !7 ! !(123 ! , 124 !) !. ! !T !h !e ! !r !e !m !a !i !n !i !n !g ! !f !a !c !t !o !r !s ! !c !o !r !r !e !s !p !o !n !d !e !d ! !m !a !i !n !l !y ! !t !o !
!a !n ! !a !d !d !i !t !i !o !n !a !l ! !c !l !a !s !s ! !I ! !b !H !L !H ! !f !a !c !t !o !r !, ! !m !I !T !F !2 ! !( !a !l !s !o ! !c !a !l !l !e !d ! !E !2 !- !2 ! !) !, ! !w !h !i !l !e ! !a ! !s !i !n !g !l !e ! !c !l !o !n !e !
!c !o !r !r !e !s !p !o !n !d !e !d ! !t !o ! !a !n !o !t !h !e !r ! !m !e !m !b !e !r ! !o !f ! !t !h !e ! !S !n !a !i !l ! !f !a !m !i !l !y !, ! !S !l !u !g ! !( !125) !. ! !F !u !n !c !t !i !o !n !a !l !
!c !h !a !r !a !c !t !e !r !i !s !a !t !i !o !n ! !o !f ! !S !n !a !i !l ! !i !n !d !i !c !a !t !e !d ! !t !h !a !t ! !i !t ! !d !o !e !s ! !i !n !d !e !e !d ! !a !c !t ! !a !s ! !a ! !s !t !r !o !n !g ! !r !e !p !r !e !s !s !o !r ! !o !f !
!t!h!e! !m!o!u!s !e! !a!n!d! !h!u!m!a!n! !E!-!c!a!d!h!e!r!i!n! !p!r!o!m!o!t!e!r!s ! (121, 123!)!.!
! I !n ! !a !l !l ! !t !h !e !s !e ! !i !n !s !t !a !n !c !e !s !, ! !t !h !e !s !e ! !r !e !p !r !e !s !s !o !r !s ! !s !i !l !e !n !c !e ! !E !- !c !a !d !h !e !r !i !n ! !b !y ! !b !i !n !d !i !n !g ! !t !o ! !t !h !e !
!p !r !o !x !i !m !a !l ! !E !- !b !o !x !e !s !, ! !a !l !t !h !o !u !g !h ! !s !o !m !e ! !d !i !f !f !e !r !e !n !c !e !s ! !a !r !e ! !o !b !s !e !r !v !e !d ! !b !e !t !w !e !e !n ! !t !h !e ! !m !o !u !s !e !
!a !n !d h !u !m !a !n ! !p !r !o !m !o !t !e !r !s !. ! !W !h !i !l !e ! !t !h !e ! !f !a !c !t !o !r !s ! !t !h !a !t ! !a !c !t ! !o !n ! !t !h !e ! !m !o !u !s !e ! !p !r !o !m !o !t !e !r ! !s !e !e !m ! !t !o !
!p !r !e !f !e !r !e !n !t !i !a !l !l !y ! !i !n !t !e !r !a !c !t ! !w !i !t !h ! !t !h !e ! !E !- !p !a !l ! !e !l !e !m !e !n !t ! !( !i !n !c !l !u !d !i !n !g ! !S !n !a !i !l !, ! !S !l !u !g ! !a !n !d ! !E !4 !7 !)
( !123, ! 124, 125 !) !, ! !i !n ! !t !h !e ! !h !u !m !a !n ! !p !r !o !m !o !t !e !r ! !e !i !t !h !e !r ! !a !l !l ! !t !h !r !e !e ! !E-b !o !x !e !s ! !o !r ! !E !- !b !o !x ! !1 ! !a !n !d ! !3 !
!a !p !p !e !a !r ! !t !o ! !b !e ! !r !e !q !u !i !r !e !d ! !f !o !r ! !t !h !e ! !i !n !t !e !r !a !c !t !i !o !n ! !o !f ! !S !n !a !i !l !/ !S !l !u !g ! !o !r ! $E !F !1 !/ !S !I !P !1 !, ! !r !e !s !p !e !c !t !i !v !e !l !y !
!( !121 !, 122, 126, 127 !) !. ! !T !h !e !s !e ! !o !b !s !e !r !v !a !t !i !o !n !s ! !s !u !g !g !e !s !t ! !t !h !a !t ! !a !t ! !l !e !a !s !t ! !t !w !o ! !o !f ! !t !h !e ! !t !h !r !e !e !
!p !r !o !x !i !m !a !l ! !E !- !b !o !x !e !s ! !i !n ! !t !h !e ! !m !a !m !m !a !l !i !a !n ! !E !- !c !a !d !h !e !r !i !n ! !p !r !o !m !o !t !e !r ! !a !r !e ! !f !u !n !c !t !i !o !n !a !l !l !y ! !s !i !m !i !l !a !r !
!i!n ! !t!e!r !m!s ! !o !f ! !r !e!c!r !u !i!t!i!n !g ! !r !e!p !r !e!s !s !o !r !s !, ! !r !e!g !a!r !d !l!e!s !s ! !o !f ! !t!h !e!i!r ! !r !e!l!a!t!i!v !e! !l!o !c!a!t!i!o !n !. ! !I !n !t!e!r !e!s !t!i!n !g !l!y !, !
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!a !l !l ! !o !f ! !t !h !e ! !E !- !c !a !d !h !e !r !i !n ! !r !e !p !r !e !s !s !o !r !s ! !i !d !e !n !t !i !f !i !e !d ! !e !x !h !i !b !i !t ! !e !x !p !r !e !s !s !i !o !n ! !p !a !t !t !e !r !n !s ! !i !n !
!d!e!v!e!l!o!p!i!n!g! !e!m!b!r!y!o!s ! !c!o!m!p!a!t!i!b!l!e! !w !i!t!h! !t!h!i!s ! !f!u!n!c!t!i!o!n!!.
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!p !r !o !c!e!s !s !e!s ! !( !116 !) !. ! !T!h !e! !s !p !e!c!i!f !i!c! !m!e!c!h !a!n !i!s !m!s ! !b !y ! !w !h !i!c!h ! !S !n !a!i!l!, ! !a!n !d !/!o !r ! !o !t!h !e!r ! !r !e!p !r !e!s !s !o !r !s !, !
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!p !r !o !m !o !t !e !r !. ! !I !n ! !t !u !r !n !, ! !t !h !i !s ! !l !e !a !d !s ! !t !o ! !a ! !c !o !m !p !a !c !t ! !o !r !g !a !n !i !s !a !t !i !o !n ! !o !f ! !t !h !e ! !c !h !r !o !m !a !t !i !n ! !( !107). !A !
!p !r !e !l !i !m !i !n !a !r !y ! !a !n !a !l !y !s !i !s ! !i !n ! !t !h !e ! !m !o !u !s !e ! !s !k !i !n ! !c !a !r !c !i !n !o !g !e !n !e !s !i !s ! !m !o !d !e !l ! !i !n !d !i !c !a !t !e !s ! !t !h !a !t ! !S !n !a !i !l !
!e !x !p !r !e !s !s !i !o !n ! !i !s ! !a !l !s !o ! !a !s !s !o !c !i !a !t !e !d ! !w !i !t !h ! !t !h !e ! !h !y !p !e !r !m !e !t !h !y !l !a !t !i !o !n ! !a !n !d ! !s !i !l !e !n !c !i !n !g ! !o !f ! !t !h !e ! !E !-
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!t !h !i !s ! !l !i !n !k ! !r !e !m !a !i !n ! !t !o ! !b !e ! !e !l !u !c !i !d !a !t !e !d !, ! !b !u !t ! !t !h !e ! !i !m !p !l !i !c !a !t !i !o !n ! !o !f ! !M !B !D !s ! !a !n !d ! !H !D !A !C !s ! !i !s ! !a !n !
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!a !f !f !i !n !i !t !y ! !f !o !r !, ! !d !i !f !f !e !r !e !n !t ! !c !o !- !r !e !p !r !e !s !s !o !r !s ! !i !n ! !s !p !e !c !i !f !i !c ! !c !e !l !l !s ! !o !r ! !t !i !s !s !u !e !s !. ! !T !h !u !s !, ! !t !h !e ! !r !e !g !u !l !a !t !i !o !n !
!o !f ! !e !x !p !r !e !s !s !i !o !n ! !a !n !d ! !f !u !n !c !t !i !o !n ! !o !f ! !t !h !e ! !d !i !f !f !e !r !e !n !t ! !r !e !p !r !e !s !s !o !r !s ! !n !e !e !d !s ! !a !l !s !o ! !t !o ! !b !e ! !t !a !k !e !n ! !i !n !t !o !
!a !c !c !o !u !n !t ! !t !o ! !o !b !t !a !i !n ! !a ! !c !o !m !p !r !e !h !e !n !s !i !v !e ! !v !i !e !w ! !o !f ! !t !h !e ! !t !r !a !n !s !c !r !i !p !t !i !o !n !a !l ! !c !o !n !t !r !o !l ! !o !f ! !E !-
!c !a !d !h !e !r !i !n !. ! !I !n ! !t !h !i !s ! !s !e !n !s !e !, ! !a ! !r !e !c !e !n !t ! !s !t !u !d !y ! !h !a !s ! !e !l !e !g !a !n !t !l !y ! !s !h !o !w !n ! !t !h !a !t ! !s !i !l !e !n !c !i !n !g ! !o !f ! !S !n !a !i !l !
!e !x !p !r !e !s !s !i !o !n ! !c !a !n ! !b !e ! !t !r !i !g !g !e !r !e !d ! !b !y ! !t !h !e ! !l !i !g !a !t !e !d ! !e !s !t !r !o !g !e !n ! !r !e !c !e !p !t !o !r ! !i !n ! !b !r !e !a !s !t ! !c !a !n !c !e !r ! !c !e !l !l !
!l !i !n !e !s !, ! !i !n !v !o !l !v !i !n !g ! !t !h !e ! !s !p !e !c !i !f !i !c ! !p !a !r !t !i !c !i !p !a !t !i !o !n ! !o !f ! !t !h !e ! !M !T !A !3 ! !p !r !o !t !e !i !n ! !i !n ! !a !n ! !a !d !d !i !t !i !o !n !a !l !
!r!e!p!r!e!s !s !o!r! !c!o!m!p!l!e!x! !(129!).
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Figura 10 A model for the regulation of E-cadherin expression involving different repressors
and epigenetic mechanisms
A schematic illustration of the putative epigenetic mechanisms involved in E-cadherin regulation
is shown. In this model, active transcription is probably achieved through the interaction of several
activators, and involves the acetylation of histone residues which promotes the chromatin to adopt
an open conformation. Under the influence of the appropriate signals, several repressors and co-
repressor molecules are recruited (depending on either the tissue or cellular context), attracting the
repressor machinery which includes corepressor molecules, HDACs and methylases, and still
unidentified molecules which will modify the acetylation and methylation status of chromatin,
promoting E-cadherin silencing (see text for details).
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2 AIMS OF THE STUDY
Thyroid tumors are the result of the accumulation of different
modifications in critical genes involved in the control of cell proliferation.
Although various therapeutic approaches are followed in clinical practice, most of
them are not life-saving. Hence, the discovery of new approach to diagnose cancer
at an early stage and to establish more effective therapies is a critical and urgent
issue. To achieve this goal, identification and characterization of key molecules
that participate in carcinogenesis are essential steps.
In this context, we studied the modulation of gene expression associated
with the progression towards a malignant phenotype of thyroid cancer. To this
aim, we used RNA samples, extracted from human thyroid carcinoma cell lines,
to perform a screening with Affymetrix microarrays containing about 10.500
human genes.
Through this approach we have identified the gene: CBX7, a chromobox family
protein which is down-regulated in thyroid carcinoma cells.
To gain insight into the role of CBX7 in malignant transformation we have
decided to perform a functional proteomic assay, because the association of CBX7
with partners involved in a particular mechanism is strongly suggestive of the
biological function of the protein (130).
Thus, the main aim of the study was the identification and characterization
of proteins that interact with CBX7 and might contribute to the transformation
process of the thyroid follicular cells
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3 MATERIALS AND METHODS
3.1 Cell culture and transfections
In this study we used the following human thyroid carcinoma cell lines:
TPC-1, WRO, NPA, ARO, FRO, NIM 1, B-CPAP, FB-1, FB-2, Kat-4 and Kat-
18, which are described elsewhere (131). They were grown in DMEM (Gibco
Laboratories, Carlsbad, CA) containing 10% fetal calf serum (Gibco
Laboratories), glutamine 10mM (Gibco Laboratories) and ampicillin/streptomycin
100 µg/ml (Gibco Laboratories). Normal human thyroid primary culture cells
have been established and grown as already described (132).
We have also used 293 Human embryonal kidney (HEK), maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% fetal
calf serum, L-glutamine, and penicillin/streptomycin.
HeLa was maintained respectively in RPMI medium supplemented
with 10% fetal calf serum, glutamine, ampicillin/streptomycin. All cell lines were
maintained at 37°C under 5% CO2 atmosphere.
Trichostatin A (TSA) (Sigma) was dissolved in ethanol and added to
the culture medium at 300 nM. A corresponding volume of ethanol was added to
control, untreated cells. TSA treatments were performed for 24 h after
transfection.
Cells were transfected using Lipofectamine reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
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3.2 Human thyroid tissue samples
Neoplastic human thyroid tissues and normal adjacent tissue or the
controlateral normal thyroid lobe were obtained from surgical specimens and
immediately frozen in liquid nitrogen. Thyroid tumors were collected at the
Laboratoire d'Histologie et de Cytologie, Centre Hospitalier Lyon Sud, France,
and at the Laboratoire d'Anatomie Pathologique, Hopital de L'Antiquaille, Lyon,
France. The tumor samples were stored frozen until RNA or protein extractions
were performed.
3.3 RNA isolation
Total RNA was extracted from tissues and cell cultures using the
RNAeasy mini kit (Qiagen, Valencia, CA), according to the manufacturer’s
instructions. The integrity of the RNA was assessed by denaturing agarose gel
electrophoresis.
3.4 Microarray analysis
In this study we used commercially available high density Affymetrix
(Santa Clara, CA) oligonucleotide microarrays (HG_U95Av2) consisting of
12.625 probe set each representing a transcript. cRNA preparation, hybridization,
scanning and analysis were performed as previously reported (133). Briefly, after
cRNA hybridization to microarray, analysis of the readings from the quantitative
scanning was performed using the Affymetrix Gene Expression Analysis
Software (Affymetrix), according to Affymetrix protocols. Comparisons were
made for each carcinoma cell line sample versus normal thyroid primary culture,
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taking normal thyroid cells as baseline. The fold change values, indicating the
relative change in the expression levels between the transformed cell line and the
normal thyroid primary culture sample, were used to identify genes differentially
expressed between these conditions.
3.5 Reverse transcription
1 µg of total RNA from each sample was reverse-transcribed with
QuantiTect® Reverse Transcription Kit (Qiagen) using an optimized blend of
oligo-dT and random primers according to the manufacturer’s instructions.
3.6 PCR analysis
Semiquantitative RT-PCR
PCR was carried out on cDNA using the GeneAmp PCR System 9600
(Applied Biosystems, Foster City, CA). The RNA PCR Core Kit (Applied
Biosystems) was used to perform amplifications. After a first denaturing step
(94°C for 3 min), PCR amplification was performed for 25-30 (variable) cycles
(94°C for 30 sec, 55-60°C (variable) for 30 sec, 72°C for 30 sec).
The sequences of primers used are shown in Table 1. To ensure that RNA
samples were not contaminated with DNA, negative controls were obtained by
carrying out the PCR on samples that were not reverse-transcribed, but otherwise
identically processed. The PCR products were separated on a 2% agarose gel,
stained with ethidium bromide and scanned with a Typhoon 9200 scanner (GE
Healthcare, Piscataway, NJ).
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Selection of primers and probes for qRT-PCR
To design a qRT-PCR assay we used the Human ProbeLibraryTM system
(Exiqon, Vedbaek, Denmark). Briefly, using locked nucleic acid (LNA
TM
)
technology (134, 135), Exiqon provides 90 human prevalidated TaqMan probes of
only 8-9 nucleotides that recognize 99% of human transcripts in the RefSeq
database at NCBI (136, 137). Using the ProbeFinder assay design software (freely
accessed on the web site www.probelibrary.com) we chose the best probe and
primers pair. To amplify a fragment of CBX7 mRNA by Real-Time PCR, we
entered its accession number (NM_175709.2) on the assay design page of the
ProbeFinder software and we chose an amplicon of 71 nucleotides that spanned
the 3rd and 4th exons. The probe number was “human 63” (according to the
numbering of Exiqon’s Human ProbeLibrary kit) and the primer sequences are
reported in Table 1.
The same procedure was used to choose the probe and primers for the
housekeeping gene G6PD (accession number X03674). We opted for an amplicon
of 106 nucleotides that spanned the 3rd and 4th exons. The probe number was
“human 05” (according to the numbering of Exiqon’s Human ProbeLibrary kit)
and the primer sequences are reported in Table 1. All fluorogenic probes were
dual-labeled with FAM at 5’-end and with a black quencher at the 3’-end.
qRT-PCR
Real-Time Quantitative TaqMan PCR was carried out with the Chromo4
Detector (MJ Research, Waltham, MA) in 96-well plates using a final volume of
20 µl. For PCR we used 8 µl of 2.5x RealMasterMixTM Probe ROX (Eppendorf
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AG, Hamburg, Germany), 200 nM of each primer, 100 nM probe and cDNA
generated from 50 ng of total RNA. The conditions used for PCR were 2 min at
95°C, 45 cycles of 20 sec at 95°C and 1 min a 60°C. Each reaction was carried
out in duplicate. Fold mRNA overexpression was calculated according to the
formula 2
(Rt-Et)
/2
(Rn-En)
 as described previously (138), where Rt is the threshold
cycle number for the reference gene in the tumor, Et for the experimental gene in
the tumor, Rn for the reference gene in the normal sample and En for the
experimental gene in the normal sample. The primers used are reported in table 1.
Symbol Acc.Num Primer F Primer R
KIF2C U63743 CAGAACAAGGCTCACACC AGCAGGCTTCCATCTCTT
CXCL1 X54489 CACCTGGATTGTGCCTAA TGCAGGCTCCTCAGAAAT
PHLDA2 AF035444 GGCACGACATGAAATCC GTGGTGACGATGGTGAAGT
CDC20 U05340 CCGTTACATTCCTTCCCT AGTTGCCCTCTTTGATCC
PIB5PA U45975 TGGAGGTGGCAGATGAGT GGATGCTGTGGTTGTGAC
TFF3 L08044 ATGTCACCCCCAAGGA TGGCAGCAATCACAGC
BTG2 U72649 ACCTCAACCTGGGGAACT CCAAACGTCTCCCACTTC
RARRES3 AF060228 GCTATCGGGTCAACAACA CCTAATCGCAAAAGAGCA
CBX7 NM_175709 GTCATGGCCTACGAGGAGAA CTTGGGTTTCGGACCTCTCT
"-ACTIN NM_001101 TCGTGCGTGACATTAAGGAG GTCAGGCAGCCTCGTAGCTCT
CBX7 qRT-PCR NM_175709 CGTCATGGCCTACGAGGA TGGGTTTCGGACCTCTCTT
G6PD qRT-PCR NM_000402 ACAGAGTGAGCCCTTCTTCAA GGAGGCTGCATCATCGTACT
Table 1 List of primers
3.7 Immunostaining: technique, evaluation and statistical analysis
The cell distribution of the CBX7 protein was assessed by immunostaining
formalin-fixed, paraffin-embedded thyroid tumor blocks retrieved from the files
of the Dipartimento di Scienze Biomorfologiche e Funzionali at the University of
Naples Federico II and selected to represent a wide range of thyroid neoplastic
diseases. To ensure that we evaluated CBX7 expression only on technically
adequate slides, we discarded slides that lacked a convincing internal control,
45
namely labeling of stromal, endothelial or lymphoid cells, shown to be positive in
a preliminary normal tissue microarray analysis (data not shown). Based on these
criteria, we scored paraffin-embedded stained slides from 20 cases of FA, 30
cases of classical PTC, 6 cases of TCV PTC, 32 cases of FTC, 12 cases of poorly
differentiated carcinoma, and 12 cases of ATC. As controls, we selected areas of
normal thyroid parenchyma from the lobe contralateral to the tumor in 20 surgical
specimens of PTC.
Briefly, xylene-dewaxed and alcohol-rehydrated paraffin sections were
placed in Coplin jars filled with a 0.01 M tri-sodium citrate solution, and heated
for 3 min in a conventional pressure cooker (131). After heating, slides were
thoroughly rinsed in cool running water for 5 min. They were washed in Tris-
buffered saline pH 7.4 and then incubated overnight with the specific rabbit
polyclonal primary antibody. Subsequently, tissue sections were stained with
biotinylated anti-rabbit immunoglobulins, and then with peroxidase-labelled
streptavidine (Dako, Carpinteria, CA). The signal was developed by using
diaminobenzidine chromogen as substrate. Incubations both omitting and pre-
adsorbing the specific antibody were used as negative controls.
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3.8 Protein extraction
For total cell extract (TCE) preparation, cells were harvested 48 hours
after the onset of transfection. Cells were then lysed in RIPA buffer (20 mM Tris-
HCl pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Nonidet P40, and a mix of protease
inhibitors), and clarified by ultracentrifugation at 13000 rpm at 4°C for 30 min.
For nuclear extract (NE), cells were washed twice in phosphate-buffered
saline and resuspended in 3 volumes of a solution containing 10 mM HEPES pH
7.9, 10 mM KCl, 1.5 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT (homogenization
solution). The cells were disrupted by passage through a 26-gauge needle. Nuclei
were collected by centrifugation at 1500 rpm. and resuspended in a 1.2-volume of
extraction solution containing 10 mM HEPES pH 7.9, 0.4 M NaCl, 1.5 mM
MgCl2, 0.1 mM EGTA, 0.5 mM DTT, 5% glycerol, to allow elution of nuclear
proteins by gentle shaking at 4°C. Nuclei were pelleted again by centrifugation at
12 000 rpm. and the supernatant was stored at -70°C until used. The protease
inhibitors leupeptin (5 mM), aprotinin (1.5 mM), phenylethylsulfunilfluoride (2
mM), peptastatin A (3 mM), and benzamidine (1 mM) were added to both
homogenization and extraction solutions. Protein concentration was determined
by the Bradford protein assay (BioRad).
For Rnase A treatment protein estracts were incubated with 10µg/ml RNase A for
10 min at 37°C.
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3.9 Western blotting and immunoprecipitation assay
Protein extracts and immunoprecipitated pellets were separated by SDS-
PAGE, and then transferred onto Immobilon-P Transfer membranes (Millipore).
Membranes were blocked with 5% non-fat milk proteins and incubated with
antibody (Ab) at the appropriate dilutions. The filters were incubated with
horseradish peroxidase-conjugated secondary antibody and the signals were
detected by Western blotting detection system (ECL) (GE Healthcare). To
ascertain that equal amounts of protein were loaded, the western blots were
incubated with antibodies against the #-tubulin protein (Sigma). Membranes were
then incubated with the horseradish peroxidase-conjugated secondary antibody
(1:3000) for 60 min (at room temperature) and the reaction was detected by ECL.
For immunoprecipitation (IP) experiments, TCE were incubated with protein A-
sepharose or G-sepharose beads (Amersham) for 1 h at 4 °C, then samples were
centrifugated to 2000 rpm to eliminate beads and incubated overnight with
antidoby. Then the IP were incubated with protein A-sepharose or G-sepharose
beads for 1 h at 4 °C. The beads were collected and washed five times with lysis
buffer, and boiled in Laemmli sample buffer for immunoblotting analysis. The Abs
used for immunoprecipitation and Western blotting were: anti-CBX7 protein
(Neosystem), anti-V5 (Invitrogen), anti-HDAC2 (Upstate), anti-HA (Roche), anti-
MDB2 (Abcam), anti-RbAp46 (Abcam), anti-PRMT5 (BD transduction
laboratories), anti-PRMT1 (Santa Cruz), anti-MTA3 (Novus Biologicals), anti-
Tubulin (Santa Cruz Biotechnology Inc.) and anti-Vinculin (Santa Cruz
Biotechnology Inc.).
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3.10 Plasmid constructs
CBX7 expression plasmid was constructed by cloning the human cDNA
sequence in a pcDNA3.1/V5-His-TOPO ® (Invitrogen). The primers used were:
CBX7 forward 5’-ATGGAGCTGTCAGCCATC-3’ and CBX7 reverse 5’-
GAACTTCCCACTGCGGTC-3’. The expression of CBX7 was assessed by
Western blotting. The same construct was also inserted in pCEFL-HA.
3.11 Samples preparation and  immunoprecipitation for proteomic assay
For preparative gels, 8x10
7
 cells were transfected with 10 µg of empty vector or
with CBX7-V5-His  expression plasmid. For immunoprecipitation experiments, 1
mg of NE were incubated for 2 hours with agarose-beads saturated with aspecific
antibody. Then the lisates were incubated with agarose anti-V5 antibodies over-
night, previously saturated with milk (Abcam). The beads were collected and
washed five times with lysis buffer, and the complex recovered by competition
with peptide V5 (Abcam). Then the lisated were incubated again with agarose
V5-beads and  the complex again recovered by competition. For immunoblotting
analysis, 50µg of TCE or immunoprecipitated proteins were separated by SDS-
PAGE and transferred to Immobilon-P Transfer membranes (Millipore).
Membranes were blocked with 5% nonfat milk proteins and incubated with the
appropriate antibodies at the appropriate dilutions. The filters were incubated
with horseradish peroxidase-conjugated secondary antibodies, and the revelations
were performed by the ECL method (Amersham Biosciences).
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3.12 Electrophoresis fractionation and in situ digestion
The immunoprecipitated protein mixture and the control were fractionated by
SDS-PAGE on a 12% bis-acrylamide gel. The gel was stained by Colloidal
Comassie (Pierce) and the corrisponding protein bands were excised from both
lanes and digested in situ with trypsin(139). Peptide mixtures were extracted,
freeze-dried and resuspended in 10 µl of 0.2% trifluoroacetic acid (TFA) for the
Liquid Chromatography/Mass Spectrometry/Mass Spectrometr (LCMSMS)
analysis
3.13 Liquid Chromatography/Mass Spectrometry/Mass Spectrometr
(LCMSMS) analysis
Each peptide mixture
 
was directly analyzed by LCMSMS using an Agilent ion
trap
 
mass spectrometer LC/MSD Trap XCT Ultra integrated with a new
microfluidic chip-based technology for nanospray LC/MS (Agilent) and coupled
on-line with a nano chromatography system Agilent 1100.
 
After loading, the
peptide mixture (8 !l) was first concentrated and washed at 4 !l/min onto a
reverse-phase
 
pre-column on the chip using 0.2% formic acid as eluent. The
sample
 
was then transferred and fractionated by reverse-phase chromatography
onto a capillary column present on the chip at a flow rate of 300 nl/min using a
linear gradient of eluent B (0.2% formic acid in 95% acetonitrile)
 
in A (0.2%
formic acid in 5% acetonitrile) from 7 to 60% in 50 min.
 
The mass spectrometer
was set up in a data-dependent MS/MS
 
mode where a full scan spectrum (m/z
acquisition range from 400 to 1600
 
Da/e) was followed by a tandem mass
spectrum (m/z acquisition range until 1800
 
Da/e). The precursor
 
ions were selected
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as the most intense peaks of the previous scan. LC/MSD Trap software, provided
by the manufacturers, was used
 
to analyze raw MS and MS/MS spectra and to
generate a peak list which was introduced in the MASCOT MS/MS ion search
software for protein identification.
3.14 Transactivation assay
In the luciferase transactivation assay HEK 293 and HeLa cells were transiently
transfected with the reporter construct (kindly provided by Dr ER Fearon,
University of Michigan Medical School) in which the luciferase gene was driven
by a fragment extending 1359 bp 5’ and 125 bp 3’to the human E-cadherin
transcription start site (104, 140) and normalized with the use of a co-transfected
"-galactosidase construct. Luciferase activity was analysed by Dual-Light System
(Applied Biosystems, Massachusetts, USA).
3.15 Expression and purification of recombinant proteins/GST pull-down
experiments
GST fusion proteins were constructed by cloning the human cDNA
sequence in a pGEX4T-1 (Promega). The primers used for GST-CBX7 were:
CBX7 forward 5’-GAGCTGTCAGCCATCGGC-3’ and CBX7 reverse 5’-
GTCAGAACTTCCCACTGCGG-3’; for GST- CBX7 CHROMO: CBX7-
CHROMO forward 5’-GAGCTGTCAGCCATCGGC-3’ and CBX7 reverse 5’-
TCACTTCTCCTTGCCCTTGGC-3’;and for GST-CBX7 NOCHROMO: CBX7-
NOCHROMO forward 5’-GCCAAGGGCAAGGAGAAGTGAC-3’ and CBX7-
NOCHROMO reverse 5’-GTCAGAACTTCCCACTGCGG-3’.
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GST fusion proteins were produced in Escherichia coli BL21 cells.
Stationary phase cultures of E. coli cells transformed with the plasmid of interest
were diluted 5–400 ml in LB with ampicillin (100 mg/ml), grown at 30°C to an
OD 600 of 0.6 and induced with 0.1mM IPTG. After an additional 2 h at 30°C,
the cultures were harvested and resuspended in 10 ml of cold PBS (140 mM
NaCl, 20mM sodium phosphate (pH 7.4)), 1mM phenylmethylsulfonyl fluoride
(PMSF) and protease inhibitors (Boehringer). The cells were broken by French
Press. For the GST proteins, the supernatant was then incubated at 4°C for 1 h
with 250 µl of glutathione-Sepharose beads (Amersham Pharmacia Biotech). The
expression of recombinant protein of CBX7 was assessed by Coomassie.
The recombinant proteins were eluted with a buffer containing PBS, 10mM
reduced glutathione, and 10% (v/v) glycerol. For GST pull-down the fusion
proteins were incubated with total cellular extracts (TCEs) in NETN buffer
(20mM Tris-HCl, pH 8.0, 100mM NaCl, 1mM EDTA, and 0.5% Nonidet P-40)
for 2 h at 4°C. The resins were then extensively washed in the same buffer and
then resuspended in Laemmli buffer. The bound proteins were separated by SDS-
PAGE and analysed by Western blotting. PRMT1 recombinant protein was
provided by Upstate.
3.16 Electrophoretic mobility shift assay (EMSA) and supershift assay
For gel shift analysis, NE were prepared following the method of Dignam,
et al (141). E-cadherin fragment were 
32
P labeled (TransCruz™ Gel Shift
Oligonucleotides) with 
32
[P]-ATP to 50,000 cpm/ng by using polynucleotide
kinase. Binding reaction mixtures (20 µl) were incubated for 20 minutes at room
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temperature in 10 mM Tris pH7.5, 50 mM NaCl 1 mM dithiothreitol (DTT), 1
mM EDTA, 5% glycerol. Binding reaction contained DNA probe (50000 cpm), 5
!g nuclear extract and 1 !g poly dI-dC to inhibit non specific binding of the
labeled probe to nuclear extract protein. The protein-DNA complexes were
resolved by native PAGE (6% gel) in 0.5xTris/borate/EDTA and visualized by
autoradiography.
For supershift analysis, assay were performed as described above with the
exception that antibody (2 ug) was normally added 4 h prior to addition of
labelled oligonucleotide probe.
3.17 HDAC activity assay
HEK 293, HeLa and NPA cells were transfected with increasing amount of
CBX7 expression vector and were used to assay the HDAC activity. The total
protein extract (30 µg) were incubated with 5 !l of [
3
H]acetate-labeled histone H4
(1.8 nCi/!g) in 200 !l of activity buffer (25 mM Tris-HCl [pH 7.5], 10% glycerol,
1 mM EDTA, 125 mM NaCl) overnight at 37°C. The reaction was stopped by the
addition of 50 !l of 1 N HCl-0.4 M acetate and the released [
3
H]acetate was
extracted with 600 !l of ethyl acetate(Upstate). After centrifugation, a 100 !l
aliquot of the supernatant was counted in 5 ml of scintillation cocktail. All
experiments were carried out three times, and samples were assayed in duplicate.
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3.18 Chromatin immunoprecipitation (ChIP) and Re-ChIP assays
ChIP and Re-ChIP experiments were performed as reported elsewhere
(142). Briefly, 5x10
6
 HEK 293 and HeLa cells were cross-linked using 1%
formaldehyde and lysed. The pellets were then resuspended in 200 µl of lysis
buffer (10mM EDTA, 50mM Tris-HCl pH 8.0, 1% SDS and protease inhibitors),
and sonicated five times for 30 sec at maximum settings, obtaining fragments
between 0.3 and 1.0 kb. The samples were cleared by centrifugation at 14 000 rpm
for 15 min. After centrifugation, 20 µl of the supernatants were used as inputs, and
the other part of the samples diluted 2.5-fold in Ip buffer (100mM NaCl, 2mM
EDTA pH 8.0, 20mM Tris-HCl pH 8.0, 0.5% Triton X-100 and protease
inhibitors).
The samples were subjected to immunoprecipitation with specific antibody
(anti-V5 described in the previous section, and anti-HDAC2) after 2 h preclearing
at 4 °C with Protein A Sepharose or Protein G Sepharose/BSA/Salmon Sperm
(Upstate). Precipitated chromatin complexes were removed from the beads through
15 min incubation with 250 ml of 1% SDS, 0.1M NaHCO3.
In Re-Chip experiments, complexes were eluted by incubation for 30 min at
37 °C in 250 µl of Re-Ip buffer and subjected again to the ChIp procedure.
Crosslink was reversed by an overnight incubation at 65°C with 20 ml of 5M
NaCl. Then were added 10 µl 0.5mM EDTA, 20 µl 1M Tris-HCl pH 6.5 and 20 µg
of Proteinase K, and incubated for 1 h at 45°C. DNA was purified by
Phenol/CHCl3, and precipitated by two volumes of ethanol in the presence of
tRNA.
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PCR was performed using specific primers:
pE-cadherin(P2)-L 5’-GAACTCAGCCAAGTGTAAAAGCC-3’
pE-cadherin(P2)-R 5’-GAGTCTGAACTGACTTCCGC-3’
p16(P1)-L 5’-GCAGTCCGACTCTCCAAAAG-3’
p16(P1)-R 5’-GGGTGTTTGGTGTCATAGGG-3’
pE2F1(P1)-L 5’-CGTTGGCTGTTGGAGATTTT-3’
pE2F1-R(P1)-R 5’-TTGCCTCACCCATGACATTA-3’
p1S100A4(P2)-L 5’-TCATCCAGTCCCCTGCTAGT-3’
p1S100A4(P2)-R 5’-AGAGCGGATACTGCCTTCCT-3’
pGAPDH(P2)-L 5’-TCCTGTTTCATCCAAGCGTG-3’
pGAPDH(P2)-R5’-GACTGTCGAACAGGAGGAG-3’
3.19 Ultracentrifugation of CBX7 transfected cells
Cells were vortexed at 4°C in ice-chilled lysis buffer. Lysis buffer L was
derived from buffer A (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl,
200 mM NaCl, 0.2 mM EDTA) supplemented with 1 mM dithiothreitol, 40 U of
RNasin (Amersham), protease inhibitor cocktail (P-8340; Sigma), and 0.5%
Nonidet P-40. Cell lysates clarified by centrifugation for 30 min at 9,000 g at 4°C
were loaded on top of 5 to 45% glycerol gradients in buffer A supplemented with
1 mM dithiothreitol and 10 U of RNasin (Amersham). The gradients were spun at
4°C for 16 h at 39 000 rpm in a Beckman SW41TI rotor. Fractions were collected
from the top of the gradients. Gradient distribution was checked by Western
blotting (143). RNAse A was provided by Fermentas.
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3.20 In vitro methyltransferase assays
10 µg of CBX7-V5 construct were transfected by Lipofectamine
(Invitrogen) into 100 mm diameter plate of HEK 293 cells. 1 µg of whole cell
extracts was immunoprecipitated with the anti-V5. The immunoprecipitates were
rinsed twice with Methylation buffer (50 mM Tris–HCl, pH 7.5, 1 mM EDTA and
1 mM EGTA) at room temperature, resuspended in 0.04 ml of Methylation buffer,
and 5 µg of pooled histones (Sigma) and 2 ml (2.75 mCi) of [H3]Ado-Met(GE
Healthcare) were added. Reactions were carried out at 30° for 30 min. Then 5 ml
of the reaction were transferred onto the center of 2cm X 2cm P81 paper
(Upstate). The square has been washed twice with 10% tricloroacetic for 15
minute and then with 95% ethanol for 5 minute. The square were dried and then
transfer in a scintillation vial, added with scintillation cocktail. PRMT1
recombinant protein was provided by Upstate.
.
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4 RESULTS AND DISCUSSION
4.1 Gene expression profile analysis of six thyroid carcinoma cell lines
compared with normal human thyroid primary cells
To search for candidate genes involved in the neoplastic transformation of
the thyroid gland, RNAs extracted from normal human thyroid primary cells and
six human thyroid carcinoma cell lines of different origin (WRO cell line from a
follicular carcinoma, TPC-1 and FB-2 cell lines, both deriving from papillary
thyroid carcinoma, NPA cell line, which derives from a poorly differentiated
papillary carcinoma, ARO and FRO cell lines originating from anaplastic
carcinomas) were hybridized to an U95Av2 Affymetrix oligonucleotide arrays
containing 12.625 sequences.
Among the transcripts represented on the array, 510 had a fold change
higher than 10 and 320 lower than -10 in most of the cell lines versus normal
thyroid cells (data not shown). To validate the results obtained by the microarray
analysis we evaluated the expression of 50 transcripts by semiquantitative RT-
PCR in a large number of thyroid carcinoma cell lines. The results essentially
overlapped those achieved by microarray analysis, thus validating them. Some
representative RT-PCR analyses are shown in Figure 11: in the panel A it is
reported the expression of some genes, such as KIF2C, CXCL1, PHLDA2 and
CDC20, that were up-regulated in thyroid carcinoma cell lines, whereas in panel B
we show the expression of same of the genes that were down-regulated in the
neoplastic cell lines, such as PIB5PA, TFF3, BTG2 and RARRES3.
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Figure 11 Validation of microarray data by semiquantitative RT-PCR
Semiquantitative RT-PCR of some up-regulated genes (A) in a panel of 11 thyroid carcinoma cell
lines versus the normal thyroid cell line (P5) and some down-regulated genes (B) resulting by the
microarray analysis. In both cases human "-Actin gene expression was evaluated as control to
normalize the amount of RNA.
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We have assumed that the up- or down-regulation of some genes in all of
the thyroid carcinoma cell lines indicate the presence of a general event linked to
thyroid cell transformation, independently from the genetic mechanisms
underlying this process. Therefore we focused on the genes up- or down-regulated
in all the carcinoma cell lines with a higher fold change. Some of them were
further analysed by other techniques.
4.2 CBX7 gene expression is down-regulated in human thyroid carcinoma
cell lines
Among the down-regulated genes, which represent potential tumor
suppression,  CBX7 was drastically down-regulated in all thyroid cancer cell lines
tested with the cDNA microarray (Figure 12A). This result was confirmed by RT-
PCR analysis in a large panel of thyroid carcinoma cell lines with normal thyroid
primary culture cells as control (Figure 12B).
59
Figure 12 CBX7 expression in human thyroid carcinoma cell lines
(A) CBX7 gene expression by microarray analysis in human thyroid carcinoma cell lines vs
normal human thyroid primary culture cells (NTPC). Avg. Diff, average difference: it is a
quantitative relative indicator of a transcript expression level ("(PM-MM)/pairs on average). (B)
CBX7 gene expression analysis by RT-PCR in human thyroid carcinoma cell lines vs the normal
human thyroid primary culture cells (NTPC). "-Actin gene expression served as loading control.
4.3 The loss of CBX7 expression correlates with a more aggressive phenotype
in thyroid carcinomas
To determine whether the loss of CBX7 expression is a feature of thyroid
tumors and not only of cultured thyroid carcinoma cell lines, we carried out an
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immunohistochemical analysis (IHC) of paraffin-embedded tissues using
polyclonal antibodies raised against the carboxy-terminal region of human CBX7
protein. As shown in Table 2, all 20 samples of normal thyroid parenchyma
expressed CBX7 at a very high level, which coincided with the strong CBX7
staining in all follicles (Figure 13A).
Table 2 CBX7 expression in normal and neoplastic thyroid tissues by IHC
a
High: cases with more than 50% of neoplastic cells showing CBX7 staining; Low: cases with less
than 50% of neoplastic cells showing CBX7 staining.
The intensity of nuclear labeling of epithelial thyroid cells in follicular
adenoma (Figure 13B) was similar to that of the internal control stromal and
endothelial cells (Figure 13G), that express normally CBX7. Conversely, CBX7
expression was reduced in malignant lesions. As shown in Table 2, and in Figure
13C and D, the percent of low expressors was high in well-differentiated tumors,
namely FTC (66%; 21/32 samples) and PTC (57%; 17/30 samples). It was even
higher in the less differentiated tumors, namely PDC (83%; 10/12) (Table 2, and
Figure 13F and G) and “tall cell variant”(TCV)-PTC (83%; 5/6) (Table 2, and
Figure 13E). In the latter, neoplastic cells were almost devoid of CBX7
expression, which sharply contrasted with the intense staining of the infiltrating
lymphocytes and stromal cells. Similarly, CBX7 expression was completely lost
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in all cases of ATC (100%; 12/12) (Table 2, Figure 13H). No staining was
observed when normal thyroid gland samples were stained with antibodies pre-
incubated with CBX7 recombinant protein (Figure 13I) or in the absence of the
primary antibodies (data not shown). Therefore, CBX7 expression was intense in
normal thyroid and in benign neoplastic lesions, decreased in well-differentiated
carcinomas and drastically reduced in aggressive thyroid tumors.
Figure 13 CBX7 staining in normal and neoplastic thyroid tissues
 CBX7 nuclear staining was intense in benign follicular epithelial cells of normal thyroid (A) and
of follicular adenoma (B), whereas it was weak in follicular carcinoma (C). CBX7 progressively
decreased going from well-differentiated “classic variant” papillary (D) carcinomas to the “tall cell
variant” of PTC (E), to poorly differentiated (F, G) and anaplastic (H) carcinomas. The signal
disappeared after incubation of the sample with antigen (I). Sample showed in the G panel is the
same of F, but magnified, to better show cell nuclei. Arrows with letters indicate the following
sample features: (P) nuclei showing cytological features of PTC negative for CBX7 expression;
(F) FTC nuclei negative for CBX7 expression; (L) lymphocyte showing CBX7 expression and
providing positive internal control; (E) endothelial cells showing CBX7 expression and providing
positive internal control.
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4.4 Analysis of CBX7 expression in normal and neoplastic thyroid tissues by
semiquantitative RT-PCR and quantitative Real-Time PCR
We also evaluated CBX7 expression by semiquantitative RT-PCR in a
panel of matched normal/tumor tissues. The results confirmed the
immunohistochemical data. In fact, there was an amplified band corresponding to
CBX7 only in normal thyroid tissues (Figure 14A).
Figure 14 CBX7 expression in thyroid tumor samples
(A) RT–PCR analysis of CBX7 expression in human thyroid tumor samples vs their normal
thyroid counterparts. "-Actin expression served as loading control. NT, normal thyroid tissue;
PTC1 to PTC6, papillary thyroid carcinomas from different patients; ATC1 to ATC5, anaplastic
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thyroid carcinomas from different patients. (B) qRT-PCR analysis of human thyroid tumor
samples of different histotypes. The fold change indicates the relative change in expression levels
between tumor samples and normal samples, assuming that the value of each normal sample is
equal to 1.
The amplified band decreased in PTC samples and almost disappeared in
ATC. qRT-PCR analysis of a large number of human thyroid carcinoma samples
of different histotypes confirmed a correlation between the reduction of CBX7
expression and a more malignant phenotype of thyroid neoplasias. In fact, as
reported in Figure 14B, there was a negative fold change in CBX7 expression
from –2.1 to –13 (average –4.8) in the PTC samples versus normal counterpart
tissues. The reduction was even more pronounced in the anaplastic carcinoma
samples, with a fold change ranging from –10.8 to –24.5 (average –14.6). These
data are well correlated with the immunohistochemical ones and suggest that
CBX7 expression is controlled at transcriptional level.
4.5 Proteomic analysis of CBX7 interacting proteins
In order to isolate and identify new CBX7 associated proteins, we
performed proteomic analysis. To this aim, an expression vector coding for the
full-length CBX7-V5,  tagged with the V5 epitope, was transiently transfected in
HEK 293 cells. The expression of CBX7 protein was verified by Western blotting
analysis using anti V5 antibody.
About 1 mg of nucleas extract (NE) was then utilized for the proteomic
analysis. In particular, proteins associated with CBX7 were purified by
immunoprecipitation (IP) using anti-V5 agarose affiniy gel antibody.
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To avoid having many aspecific proteins eluted in the loading buffer in
the gel we have eluted the IP by competition with peptide V5. Preliminary SDS-
PAGE experiments of the immunoprecipitated proteins showed a large number of
protein bands. Therefore, before performing the preparative assay we have
confirmed the expression of the CBX7-V5 construct in HEK 293 cells and the
efficiency of the immunoprecipitation assay with anti-V5 agarose affinity gel
antibody (Figura 15A). Then, the preparative immunoprecipitated material was
fractionated on a 12% one-dimensional (1D) gel. Preparative gel was stained with
Blue Coomassie as shown in the figure 15B.
CBX7-V5 -   +    -    +
WB: -V5
IP: -V5A
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Figure 15 Proteomic analysis
A part of IP of empty vector and CBX7-V5 vector transfected HEK 293 cells were first
fractionated on a 12% SDS-PAGE gel to verify the expression of CBX7 vector and the efficiency
of the  immunoprecipitation (A) and then on one-dimensional gel for proteomic assay. Next, the
preparative gel was stained with Blue coomassie as shown in the figure (B) (M:marker)
The comparison between the “empty-vector” lane, corresponding to the
immunoprecipitated lysate from empty-vector transfected cells, and the “CBX7-
V5” lane, which corresponds to that of CBX7 overexpressing cells, allowed us to
identify several bands that were present only in the “CBX7-V5” lane and absent
in the control. Then, both gel lanes were sequentially cut in several fragments as
shown in figure 16. Each protein band was digested in situ with trypsin (139) and
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the peptide mixture obtained was directly analyzed by Liquid chromatography
tandem mass spectrometry (LCMSMS).
Figura 16 Proteomic analysis
IP of empty vector and CBX7-V5 were fractionated on one-dimensional gel. Preparative gel was
stained with Blue coomassie and the gel was sequentially cut in several fragments covering all
lane as shown in the figure (M:marker; number indicates a putative unique band)
The peak list of the peptides was introduced in the MASCOT MS/MS ion
search software for protein identification. The final results are summarized in
Table 3 (after the REFERENCES), where the names, accession numbers and
function of the identified proteins are reported. It was not surprising that each
excised band from 1-D gel separation contained more than one protein. We have
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also clustered CBX7 interacting proteins observing that there are many proteins
involved in DNA regulation, export and metabolism.
 Generally, two peptide sequences are sufficient to identify a single
protein, together with information about the score of peptides.
In our proteomic experiment we identified the bait CBX7 on the basis of a single
peptide sequence, because the protein was not abundant; for this reason we
decided to take in consideration proteins present exclusively in the CBX7 IP even
if identified by just a single peptide recognition.
After MASCOT analysis we analized only the proteins that were present in the IP
of CB7-V5.
4.6 In vitro characterization of CBX7 molecular complexes
All CBX7 putative partners identified by the proteomic approach still
needed to be confirmed by independent experiments, such as GST pull-down or
co-IP.
Among CBX7 interacting protein, we selected the HDAC2 because of its
relevance in tumour biology.
To examine the specificity of this interactions and to map the regions of
CBX7 proteins required for the binding to its molecular interactors, pull-down
assays were performed incubating a total lysate deriving from HEK 293 cells
with the CBX7 recombinant protein fused to GST and with two deletion mutants
of CBX7, GST- CBX7 CHROMO  and GST-CBX7 NOCHROMO, lacking from
55 to 251 aa  and from 1 to 55 aa,  respectively (Figure 17).
First, we analyzed the interaction between CBX7 and HDAC2. No associated
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proteins were detectable in the complexes obtained incubating TCE with the GST
protein alone or with the GST-CBX7 CHROMO fusion protein. Instead there was
interaction between GST-CBX7 or the GST-CBX7 NOCHROMO mutant and
HDCA2. These results clearly show that the interaction between CBX7 and
HDCA2 involves the region of CBX7 outside the Chromodomain. Gels were
stained with Blue coomassie to show that equal amount of GST-fusion proteins
were used for the pull-down assay (data not shown).
Figura 17  CBX7 interacts in vitro with HDAC2
5µg of each recombinant protein were incubated with 1 mg of TCE for 2 h. Then the beads were
washed, the complexes resuspended in loading buffer and loaded on SDS-PAGE. The filter was
incubated with antibody against HDAC2.
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4.7 CBX7 physically interacts with HDAC2 protein
To verify the CBX7/HDAC2 interaction in vivo, HEK 293 cells were
transiently transfected with the V5-tagged-CBX7 expression vector. Protein
lysates were immunoprecipitated with anti-V5 antibody and immunoblotted with
anti-V5 and anti-HDAC2 antibodies. As shown in Figure 8, we were able to
detect the association between CBX7 and the endogenous HDAC2 protein,
demonstrating that CBX7 and HDAC2 form complexes in vivo. The reciprocal
experiment was performed immunoprecipitating with anti-HDAC2 and revealing
with anti-V5 antibodies: it confirmed the interaction between the HDAC2 and
CBX7 proteins (data not shown).
Figura 18 HDAC2/CBX7 in vivo interaction by co-immunoprecipitation
HEK 293 cells were transfected with V5-tagged-CBX7 vector and, after 48 h, total cell extracts
were prepared and equal amounts of proteins were immunoprecipitated with anti-V5 antibodies.
The immunocomplexes were analysed by Western blotting using anti-HDAC2 antibodies. The
relative inputs are total cell extracts derived from HEK 293 untransfected cells. IgG indicates the
negative control of immunoprecipitation using an unrelated antibody.
4.8 CBX7  inhibits HDAC activity
In order to evaluate the effects of the CBX7/HDAC2 interaction on the
HDAC2 activity, we performed an HDAC activity assay on HEK 293 cells
overexpressing CBX7.
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As shown in figure 19A, CBX7 inhibited HDAC activity, almost as
strongly as sodium butyrate (NaB), a robust HDAC inhibitory compound (144),
used as positive control. In figure 19B the CBX7 expression levels in transfected
cells are shown.
Figura 19 HDAC activity assay.
HEK 293 cells were transfected with empty vector(-) and CBX7 expression vector. (A) Nuclear
extracts were assayed for HDAC activity after 48 h. (B)Samples treated with sodium butyrate
(NaB) were used as positive control. Values represent the average of three experiments +/-
SD(lower panel). Aliquots of the same lysates were resolved by SDS-PAGE, transferred to
nitrocellulose membrane, and immunoblotted with the indicated antibodies.
A
B
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To further confirm the inhibitory activity exerted by CBX7 on HDAC2
activity, we transfected HeLa  and NPA cells with different amount of CBX7.
Remarkably, CBX7 inhibited the HDAC activity in the cell lines used in a
dose-dependent manner (the percentage of inhibition was 65,15% and 42,55% in
HeLa and NPA cells respectively, after the transfection of 10 !g of CBX7)
(Figure 20). Again as positive control for HDAC inhibition we used sodium
butyrate (NaB) (144).
Figura 20 HDAC activity assay in Hela and NPA
HeLa and NPA cells were transfected with increasing amounts of CBX7 expression vector and
nuclear extracts were assayed for HDAC activity after 48 h. Samples treated with sodium butyrate
(NaB) were used as positive control. Values represent the average of three experiments +/- SD.
Aliquots of the same lysates were resolved by SDS-PAGE, transferred to nitrocellulose
membrane, and immunoblotted with the indicated antibodies (lower panel)
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4.9 CBX7  and HDAC activity in tumors
As previously shown by RT-PCR and immunohistochemistry, CBX7 was
strongly down-regulated in tumors. Therefore, we investigated HDAC activity in
normal thyroid in comparison to anaplastic tumor (ATC) histotype. As expected,
in absence of CBX7 there was an increase in HDAC activity (figure 21).
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Figura 21 HDAC activity assay in anaplastic tumors (ATC)
Normal thyroid and sample of ATC were assayed for HDAC activity. Values represent the average
of three experiments +/- SD.
4.10 CBX7 binds to E-cadherin gene promoter in vivo
HDACs catalyze the removal of acetyl groups from core histones (145). Because
of their capacity to induce local condensation of chromatin, HDACs are generally
considered repressors of transcription (145) and it is already known that HDAC2
is able to repress E-cadherin promoter (146). Given that CBX7 is a protein that
probably binds chromatin, we asked whether the physical interaction between
CBX7 and HDAC2 takes place on the human E-cadherin promoter, an important
marker of EMT. Therefore, we first evaluated whether CBX7 protein binds the E-
cadherin promoter in vivo by performing ChIP assays. HEK 293 and HeLa cells
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were transfected with HA-tagged-CBX7 expression vector, crosslinked, and
immunoprecipitated with anti-HA or anti-IgG antibodies. Immunoprecipitation of
chromatin was subsequently analysed by semiquantitative PCR, using primers
spanning the region of the E-cadherin promoter (300 bp upstream to 40 bp
downstream to the transcription start site). Anti-HA antibodies precipitated this E-
cadherin promoter region from HEK 293 and HeLa cells transfected with HA-
tagged-CBX7 protein (Figure 22). No immunoprecipitation was observed with
anti-IgG precipitates and with primers for the control promoter GAPDH
indicating that the binding is specific for the E-cadherin promoter. We performed
also PCR amplification of the immunoprecipitated DNA using primers for p16,
E2F1 and S100A4 gene promoter to validate the presence of the CBX7 on the
promoters of other genes.
Similar results were obtained when the NPA cells were used (data not
shown). These results indicate that CBX7 protein binds the E-cadherin promoter
region in vivo.
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Figure 22 CBX7 binds to the E-cadherin promoter in vivo
 Soluble chromatin from HEK 293 and HeLa cells transfected with HA-tagged-CBX7 was
immunoprecipitated with anti-HA antibody. The DNAs were then amplified by PCR using primers
that cover a region of human E-cadherin promoter (300 bp upstream to 40 bp downstream to the
transcription start site). As an immunoprecipitation control, IgG was used. The panel shows also
PCR amplification of the immunoprecipitated DNA using primers for p16, E2F1, S100A4 and
GAPDH gene promoter
4.11 CBX7 occupies the E-cadherin promoter with HDAC2
To determine whether CBX7 occupies the E-cadherin promoter together
with HDAC2, the anti-HA complexes were released, re-immunoprecipitated with
anti-HDAC2 antibodies, and then analyzed by semiquantitative PCR (Re-ChIP).
The results shown in the Figure 23 reveal that the antibodies against HDAC2
precipitate the E-cadherin promoter after their release from anti-HA, indicating
that CBX7 occupies this region together with HDAC2. The reciprocal experiment
provided comparable results (data not shown). Taken together, these results
indicate that CBX7 binds to the human E-cadherin promoter in vivo, and
participate in the same DNA-bound complex containing HDAC2.
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Figure 23 Re-ChIP experiment on E-cadherin promoter
In Re-ChIP experiments, soluble chromatin from transfected HEK 293 and HeLa cells was
immunoprecipitated with anti-HDAC2 antibody, eluted, and reimmunoprecipitated with anti-HA.
The purified DNA was used as template for PCR using the same primers described in figure 22.
4.12 CBX7 and E-cadherin expression are correlated in human thyroid
carcinomas
In order to evaluate if the CBX7 binding to E-cadherin promoter could
paly a role in thyroid carcinogenesis, the next step was to analyze E-cadherin
expression in human thyroid carcinomas of different histotypes. As shown in the
Figure 24 a positive correlation was found between CBX7 and E-cadherin
expression. In fact, E-cadherin mRNA levels were drastically reduced in the ATC
samples, whereas just a weak decrease was observed in the PTC ones. CBX7
expression showed the same trend when the same samples were analyzed.
Immunohistochemical analysis confirmed that E-cadherin protein levels paralleled
CBX7 protein levels (data not shown). These results are consistent with other
reported data showing a down-regulation of the E-cadherin gene in human
carcinomas of diverse anatomic origin characterized by a highly aggressive
phenotype (107).
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 Figure 24 CBX7 and E-cadherin expression in fresh thyroid tumour samples analysed by
qRT-PCR
The fold change indicates the relative change in expression levels between tumour samples and
normal samples, assuming that the value of each normal sample is equal to 1. PTC, papillary
thyroid carcinoma; ATC, anaplastic thyroid carcinoma. Numbers indicated the patients.
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4.13 CBX7 modulates E-cadherin gene transcription
To evaluate the effect of CBX7 expression on E-cadherin transcription,
HEK 293 cells were co-transfected with an expression vector encoding CBX7 and
with a reporter vector carrying the luciferase gene under the control of the E-
cadherin promoter. As shown in Figure 25, CBX7 was able to increase the
transcriptional activity of the E-cadherin promoter in a dose-dependent manner.
Conversely, no increase of luciferase activity was observed when CBX7 was co-
transfected with the luciferase vector without E-cadherin promoter (data not
shown).
Figure 25 Activity of CBX7 on the E-cadherin promoter
Dose-response analysis of increasing amounts of CBX7 on the E-cadherin luciferase-reporter
vector transiently transfected into HEK 293 cells. All transfections were performed in duplicate
and the data are mean +/- SD of three independent experiments. Cells transfected with the
backbone vector were used as control. Western blot for CBX7 from one representative experiment
is shown in the lower panel. Vinculin was used to normalize protein loading.
78
The treatment of cells with trichostatin (TSA), a potent inhibitor of HDAC
activity (147) was able to synergize with CBX7 in induce E-cadherin gene
transcription (Figure 26). This results strongly suggest that CBX7 protein is
involved in the E-cadherin gene transcription, likely counteracting the inhibitory
effect of HDAC2 on this gene promoter.
Figure 26 The CBX7 activity on the E-cadherin promoter is inhibited by HDAC inhibitor
Luciferase activities of extracts from HEK 293 cells cotransfected with the E-cadherin luciferase-
reporter vector, increasing amounts of CBX7 and treated with the HDAC inhibitor trichostatin A
(TSA) at 300 nM final concentration. All transfections were performed in duplicate and the data
are mean+/- SD of three independent experiments.
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4.14 In vivo characterization of CBX7 molecular complexes
To validate the interaction between CBX7 protein and some of the newly
identified associated proteins in vivo, total cellular extracts from HEK 293 cells
transfected with the empty vector or with the full-length CBX7 cDNA tagged
with the V5 epitope were immunoprecipitated with the antibodies against V5 and
transferred on filters that were subsequently immunoblotted with anti-V5 or
antibodies against each interacting protein. As shown in Figure 27, a great
amount of CBX7 protein was present in all of the immunocomplexes from HEK
293 cells overexpressing CBX7 protein, confirming that CBX7 and the indicated
proteins really interact.
To examine the effective amount of the molecular interactors identified in
HEK 293 cells, we evaluated their protein levels in empty vector or CBX7-
overexpressing cells by Western blotting analysis. As shown in the Figure 27, the
amount of each protein in these cells was comparable. As control, we confirmed
the expression of CBX7 in transfected HEK 293 cells using anti-V5 antibody.
These experiments demonstrate that the interactions, evaluated through proteomic
analysis, are real, and that CBX7 protein belongs, at least in this cellular system,
to new molecular complexes. We have performed the co-immunoprecipitation for
other three proteins. In particular, MTA3 which might be a component of the
same complex of CBX7 on the E-cadherin promoter and PRMT1 and PRMT5
could have a regulatory function in arginine methylation together with CBX7.
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Figure 27 Confirmation of CBX7 interactions by co-immunoprecipitation
HEK 293 cells were transfected with V5-tagged-CBX7 vector and 48 h after transfection total cell
extracts were prepared and equal amounts of proteins were immunoprecipitated with anti-V5
antibodies. The immunocomplexes were analysed by Western blotting using the indicated
antibodies. The relative inputs are total cell extracts derived from HEK 293 untransfected and
transfected cells.
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4.15 Fractionation of CBX7-V5 transfected cells, with or without RNase A
treatment
It has already been shown that CBX7 interacts also with RNA (84). To
assay if the complexes of CBX7 are dependent on RNA binding we perfomed a
fractionation on glycerol-gradient with and without RNase A, an
endoribonuclease that specifically degrades single-stranded RNA.
We transfected HEK 293 cells with empty or CBX7-V5 expressing vector
and performed NE. We treated 2 mg of NE of CBX7-V5 with RNase A and other
2 mg of NE with RNasin, an RNase inhibitor. Then we loaded the two samples of
CBX7-V5 transfected cells on top of two 5 to 45% glycerol gradients. The
gradients were spun at 4°C for 16 h at 39 000 rpm. Ten fractions were collected
from the top of the gradients(1 to 10) plus a pellet(11).
To validate if RNAse A treatment changes the distribution of CBX7
complexes we analyzed all fractions by SDS-PAGE. To check the efficacy of the
sedimentation we followed the sedimentation of CDK9, one of two component of
Positive Transcription Elongation Factor b (P-TEFb). P-TEFb, a cyclin-dependent
kinase, comprised of Cdk9 and in humans one of three cyclins, T1, T2, or K, is
the key factor regulating eukaryotic mRNA transcription at the level of
elongation. As well described in literature, P-TEFb sediments in two sets of
fractions (143). Upper fractions contain active core P-TEFb, whereas the large
kinase-inactive P-TEFb/7SK RNA complex is found in the lower fractions.
We found that the sedimentation of CBX7-V5 not change after treatment
with RNAse, while P-TEFb sediments were in two sets of fractions (figure 28)
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thus demonstrating that the complexes of CBX7 were not influenced by binding
with RNA.
Figure 28 TCE separation by ultracentrifugation of CBX7-V5 transfected cells treated with
RNase A
CBX7-V5 construct was transfected in HEK 293 cells and TCE was fractionated into 10 fractions
(1-10) plus a pellet (11) by ultracentrifugation on a 5-45% glycerol-gradient. The fractions
recovered were loaded on SDS-PAGE and analyzed for V5 expression. As control we followed the
sedimentation of CDK9 (a component of p-TEFb) that sediment in two components.
4.16 Sedimentation of CBX7-V5 interacting proteins
In order to verify the segregation of CBX7-V5 interacting proteins we
transfected HEK 293 cells with CBX7-V5 expressing vector. TCE were
fractionated into 10 fractions (1-10) plus a pellet (11) by ultracentrifugation on a
5-45% glycerol-gradient. The fractions recovered were loaded on SDS-PAGE and
analyzed for CBX7 interacting proteins, identified by the proteomic experiment,
or proteins that have already been described in the same pathway (figure 29).
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Figure 29 TCE separation of CBX7-V5 transfected cells
CBX7-V5 was transfected in HEK 293 cells and TCE was fractionated into 10 fractions (1-10)
plus a pellet (11) by ultracentrifugation on a 5-45% glycerol-gradient. The fractions recovered
were loaded on SDS-PAGE and analyzed for the expression of V5 and other proteins.
4.17 Characterization and function of CBX7 complexes
In an attempt to identify the CBX7 complexes that bind to the E-cadherin
promoter we  performed an EMSA assay. First, NE were extracted from HEK 293
cells transfected with an empty or a CBX7-V5 expressing vector. We performed
ChIP experiments to verify the site of action of CBX7 on the E-cadherin promoter
and to identify the minimal site to perform EMSA experiments (data not shown).
We  identified a fragment of E-cadherin promoter containing an E-box.
So we first performed an EMSA assay analyzing the capacity of nuclear
extracts (5 µg)  from  HEK 293 cells transfected with an empty vector or a CBX7-
V5 to bind a E-cadherin oligonucleotide, as we have seen in ChIP and Re-ChIP
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experiments.
NE containing empty or CBX7-V5 expressing vector binds E-cadherin
oligonucleotide specifically, forming complexes with various electrophoretic
mobilities (complex A, B and D). When HEK 293 cells were transfected with
CBX7-V5 we observed the formation of a fourth complex (C) (figure 30).
Binding specificity was demonstrated by competition experiments
showing loss of binding on all the three complexes with the addition of a 100-fold
molar excess of unlabelled E-cadherin oligonucleotide. In particular, in HEK 293
cells transfected with CBX7-V5 there was also the disappearence of the CBX7
specific complex (complex C).
Figure 30 CBX7 binds to the E-cadherin promoter in vitro
EMSA performed with a radiolabelled oligonucleotide containing a fragment of the E-cadherin
promoter (including E-Box) incubated with nuclear extracts (5 µg)  from HEK 293 cells
transfected with an empty vector or the CBX7-V5 expression vector. To assess the specificity of
the binding, nuclear extracts protein was incubated in the presence of a 100-fold excess of
unlabelled oligonucleotide used as competitor.
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In an attempt to determine the composition of these complexes and the
presence of proteins identified by proteomic assay, we used specific antibodies
directed against the CBX7 interacting proteins in a supershift analysis.
We observed a significant supershift (complex E) with the antibody against
Protein arginine N-methyltransferase 1 (PRMT1) in the lane with CBX7-V5
transfected cells extracts, indicating that PRMT1 partecipates in CBX7 complex
(complexC) on E-cadherin promoter. (figure 31).
Figure 31 CBX7 and PRMT1 on E-cadherin promoter
EMSA performed with a radiolabelled oligonucleotide containing a fragment of the E-cadherin
promoter (including E-Box) incubated with nuclear extracts (5 µg)  from HEK 293 cells
transfected with an empty vector or the CBX7-V5 expression vector. To assess the specificity of
the binding, nuclear extracts protein was incubated in the presence of a 100-fold excess of
unlabelled oligonucleotide used as competitor and with the antibody indicated. Arrows indicate
specific complexes DNA/proteins.
Instead, in the case of the Metastasis associated 1 family, member 3,
(MTA3) supershift  the presence of antibody against MTA3 increased the binding
of complex C to the E-cadherin oligonucleotide and decreased the amount of
complex A (figure 32).
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Figure 32 CBX7 and PRMT1 on E-cadherin promoter
EMSA performed with a radiolabelled oligonucleotide containing a fragment of the E-cadherin
promoter (including E-Box) incubated with nuclear extracts (5 µg)  from HEK 293 cells
transfected with an empty vector or the CBX7-V5 expression vector. To assess the specificity of
the binding, nuclear extracts protein was incubated in the presence of a 100-fold excess of
unlabelled oligonucleotide used as competitor and with the antibody indicated. Arrows indicate
specific complexes DNA/proteins.
4.18 CBX7 and  Protein arginine N-methyltransferase 1 (PRMT1)
In order to better investigate the interaction between CBX7 and PRMT1 we
performed a histone methyl transferase assay to validate:
a) If CBX7 has an associated arginine methylase activity, as suggested by the
verified association with PRMT1;
b) if CBX7 is a substrate of PRMT1, as suggested by the evidence that the
aminoacid sequence of CBX7 has two possible site for argine methylation.
To verify the first point we transfected HEK 293 cells with CBX7-V5 and
immunoprecipitated with antidoby against V5.
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Then, we assayed the ability of  the immunoprecipitated proteins, i.e. the proteins
interacting  with CBX7,  as PRMT1, to methylate arginine of the substrate.
In this assay we used as control a recombinant PRMT1 and as substrate core
histones (figure 33).
Figure 33 Histone methyltransferase assay
HEK 293 cells transfected with CBX7-V5 and immunoprecipitated were assayed for arginine
methyltransferase activity (+IP: immunoprecipitation of CBX7-V5, -IP: negative control of
immunoprecipitation, without antibody, PRMT1 is the positive control of the assay)
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5 CONCLUSIONS
Thyroid tumors result from the accumulation of different modifications in
critical genes involved in the control of cell proliferation. Although various
therapeutic approaches are followed in clinical practice, most of them are not life-
saving. Hence, the discovery of new approach to diagnose cancer at an early stage
and to establish more effective therapies is a critical and urgent issue. To achieve
this goal, identification and characterization of key molecules that participate in
carcinogenesis are essential steps.
In this study we show that, by the use of cDNA microarray, it is possible
to identify genes potentially involved in human cancers. In fact we identified
CBX7, that could be actively involved in the process of thyroid carcinogenesis.
CBX7 is abundantly expressed in normal thyroid gland, but its expression
decreased with malignancy and neoplasia stage. In fact, CBX7 expression was
comparable to normal thyroid tissue in benign follicular adenomas, slightly
reduced in papillary thyroid carcinomas displaying the classical histotype, and
drastically reduced, and in most cases absent, in follicular thyroid carcinomas, in
the tall cell variant of papillary thyroid carcinomas, in poorly differentiated and in
anaplastic thyroid carcinomas. Thus, it is feasible that CBX7 levels could serve to
differentiate between benign and malignant thyroid neoplasms.
In order to study CBX7 function in normal cells and understand why it is
drastically down-regulated in thyroid cells, we have decided to investigate
proteins interacting with CBX7, by a proteomic assay. Proteomic assays are very
useful because the association of CBX7 with partners belonging to a specific
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protein complex involved in a particular mechanism is strongly suggestive of the
biological function of the protein (130).
In particular in our investigation we have found that CBX7 regulates an
key mediator of EMT, E-cadherin, through HDAC2 activity.
EMT describes a series of events during which epithelial cells loose many
of their epithelial characteristics and take on properties that are typical of
mesenchymal cells, which require complex changes in cell architecture and
behaviour. During progression of the tumor, carcinoma cells acquire
mesenchymal gene-expression patterns and properties (90).
One of the hallmarks of EMT is the functional loss of E-cadherin (encoded
by CDH1), which is currently thought to be a suppressor of invasion during
carcinoma progression (96).
We demonstrated that CBX7 interacts with HDAC2, and is able to inhibit
its activity in HeLa and in thyroid carcinoma cell lines. This result, by itself, may
account for the increased aggressiveness of the neoplasias lacking CBX7
expression. In fact, HDACs are generally considered repressors of transcription,
and HDAC activity is generally increased in human neoplasias, and, consistently,
HDAC inhibitors represent a novel therapeutic strategy for cancer treatment (148).
 Interestingly, we were able to demonstrate that both HDAC and CBX7
bind the E-cadherin promoter, and that CBX7 contrasts the inhibiting effect of
HDAC on E-cadherin expression. This led us to hypothesize that the loss of
CBX7 expression occurring in ATCs results in an increased HDAC activity on the
E-cadherin promoter, then switching off its expression.
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Consistently, E-cadherin expression essentially parallels CBX7 expression
in thyroid carcinomas. Moreover, no E-cadherin promoter hypermethylation,
frequently observed in other human neoplasias (107), has been detected in ATC
(Sacchetti et al., unpublished data), suggesting that epigenetic mechanisms as
those described here, may account for the silencing of the E-cadherin gene. Of
course, it is reasonable to hypothesize that CBX7 may control through the same or
other mechanisms the regulation of other genes involved in cell growth regulation
and invasion.
In this scenario, we speculate that CBX7 could exert its effect on thyroid cancer
progression also interacting with PRMT1 (Protein arginine N-methyltransferase 1)
and MTA3, (metastasis associated 1 family, member 3).
PRMT1 is an arginine methyltransferase that is described to methylate
H4R3, thus inducing transcription (149-152). Frequently PRMT1 methylates the
same residues of PRMT5 as in the case of SPT5, that we have also found in our
proteomic assay (153, 154). SPT5 and its binding partner SPT4 function both
positively and negatively in regulating transcriptional elongation. SPT5 is
specifically associated with PRMT1 and PRMT5. Also H4R3 is a site of
methylation of both PRMT, with opposite consequences.
Sometimes deacetylation of the promoters is a prerequisite for PRMT5-
mediated H3 and H4 arginine methylation (150). It is suggestive in case of CBX7
and HDAC2 on E-cadherin promoter. It has been also described the association of
PRMT5 with Sin3A/HDAC2 complex (155).
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Moreover, we have also to remember that CBX7 is described to interact
with RNA and methylation of arginine is a common feature of RNA binding
proteins (84).
Also the interaction of CBX7 with MTA3 could be very important. MTA3
has been yet described as a regulator of E-cadherin expression by transcription
factor Snail in breast cells through a mechanism HDAC1/2 dependent (129, 156).
For this reason it is very suggestive that CBX7 mediates activation of E-cadherin
repressing HDAC2 activity.
 It should be interesting to investigate the relationship of CBX7 and MTA3
in regulating E-cadherin. Infact, it has been also described the interaction of
PRMT5 with HDAC2 and MTA3 (157).
In our proteomic experiment we have also identified many proteins
involved in mRNA maturation, splicing and elongation. PRMT1 regulates also
poly(A) binding protein in fission Yeast, another protein that interacts with CBX7
(158).
 Protein that bind RNA have generally a common feature (RG) that is a site
of methylation on  arginine. So these data are in agreement with preliminary data
suggesting  a role for CBX7 in splicing and regulation of elongation.
As suggested by  many important interacting protein of CBX7 and the
pathway in which they are involved, CBX7 can be considerated a very important
regulator of thyroid transcription and malignant transformation and a target of
therapy.
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TABLE 2 CBX7 interacting proteins
BAND PROTEIN ID score
N°
peptidi
MW Function Process
T1
(P62826) GTP-binding nuclear protein
Ran (GTPase Ran) (Ras-like protein
TC4)
27 2 25
GTP-binding protein involved in nucleocytoplasmic transport. Required for the
import of protein into the nucleus and also for RNA export. Involved in chromatin
condensation and control of cell cycle.Nuclear; becomes dispersed throughout the
cytoplasm during mitosis. Interact with RANGAP1
 GTPase activity/ Signal
transduction ; Cell communication
T4
(P61981) 14-3-3 protein gamma (Protein
kinase C inhibitor protein 1)
88 1 28
Adapter protein implicated in the regulation of a large spectrum of both general and
specialized signaling pathway. Binds to a large number of partners, usually by
recognition of a phosphoserine or phosphothreonine motif. Binding generally results
in the modulation of the activity of the binding partner.Interacts with RAF1 and
SSH1.Cytoplasm.
Receptor signaling complex
scaffold activity/ Signal
transduction; cell communication
T5 (O95931) Chromobox protein homolog 7 40 1 28 BAIT
(P04083) Annexin A1 (Annexin I)
(Lipocortin I) (Calpactin II)
(Chromobindin-9)
785 19 39
Calcium/phospholipid-binding protein which promotes membrane fusion and is
involved in exocytosis. This protein regulates phospholipase A2 activity. It seems to
bind from two to four calcium ions with high affinity.Phosphorylated by protein
kinase C, epidermal growth factor receptor/kinase and TRPM7. Phosphorylation
results in loss of the inhibitory activity.
   Calcium ion binding/Signal
transduction ; Cell communication
(P07355) Annexin A2 (Annexin II)
(Lipocortin II) (Calpactin I heavy chain)
(Chromobindin-8)
284 5 39
 Calcium-regulated membrane-binding protein whose affinity for calcium is greatly
enhanced by anionic phospholipids. It binds two calcium ions with high affinity
   Calcium ion binding/Signal
transduction ; Cell communication
T7
(Q08188) Protein-glutamine gamma-
glutamyltransferase E precursor
231 6 77
Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins.
It is responsible for the later stages of cell envelope formation in the epidermis and
the hair follicle
Transaminase activity/
Metabolism; Cell growth and/or
maintenance
gi|37183160 HRPE773 [Homo sapiens] 215 7 20 Q96DA0 HUMAN Similar to common salivary protein 1 Unknown
 gi|662841 heat shock protein 27 147 5 22
Involved in stress resistance and actin organization. Associates with alpha- and beta-
tubulin and microtubules. Interacts with HSPB8.Cytoplasm. Nucleus. Cytoplasmic in
interphase cells. Colocalizes with mitotic spindles in mitotic cells. Translocates to the
nucleus during heat shock.
Chaperone activity/Cell
proliferation
gi|20334354 S100 calcium binding
protein A14
144 2 12 Cytoplasm.
   Calcium ion binding/Biological
Process Unknown
gi|4885607 small proline-rich protein 3
[Homo sapiens]
132 3 19 Cross-linked envelope protein of keratinocytes. Cytoplasm.
Structural molecule activity/ Cell
growth and/or maintenance
gi|31645 glyceraldehyde-3-phosphate
dehydrogenase [Homo sapiens]
110 4 36
It has been suggested that glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
play a role in nuclear tRNA export
Catalytic activity/ Nuclear export
gi|187302 epithelial cell marker protein 1
(14-3-3 sigma)
90 2 28
 Adapter protein implicated in the regulation of a large spectrum of both general and
specialized signaling pathway. Binds to a large number of partners, usually by
recognition of a phosphoserine or phosphothreonine motif. Binding generally results
in the modulation of the activity of the binding partner. p53-regulated inhibitor of
G2/M progression. Cytoplasm. Or: Secreted protein. May be secreted by a non-
classical secretory pathway. Belongs to the 14-3-3 family.
  Receptor signaling complex
scaffold activity /Signal
transduction ; Cell communication
gi|45592961 chromosome 20 open
reading frame 70 [Homo sapiens]
76 2 27
containing a lipid binding domain - similar to short palate, lung and nasal epithelium
carcinoma-associated protein 2
Unknown/Biological Process
Unknown
gi|18204442  Ribosomal protein L18 64 1 22 Ribosomal protein
Ribosomal subunit/ Protein
metabolism
 gi|895845 p64 CLCP 62 1 24
Seems to act as a chloride ion channel.. Mostly in the nucleus including in the
nuclear membrane. Cytoplasm. Cell membrane. Small amount in the cytoplasm and
the plasma membrane.SIMILARITY: Belongs to the chloride channel CLIC family.
SUBCELLULAR LOCATION: Nucleus; nuclear membrane
Transmembrane receptor activity/
receptor
(P09651) Heterogeneous nuclear
ribonucleoprotein A1 (Helix-destabilizing
protein)
58 1 39
Involved in the packaging of pre-mRNA into hnRNP particles, transport of poly(A)
mRNA from the nucleus to the cytoplasm and may modulate splice site selection.
Nucleus. Cytoplasm. Shuttles continuously between the nucleus and the cytoplasm
along with mRNA. Component of ribonucleosomes.
  Ribonucleoprotein/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism/
Nucleus export
T8
gi|627650 transcription factor BTF2 chain
p34 - human
56 1 35
FUNCTION: Component of the core-TFIIH basal transcription factor involved in
nucleotide excision repair (NER) of DNA and, when complexed to CAK, in RNA
transcription by RNA polymerase II. Anchors XPB.SUBUNIT: One of the six
subunits forming the core-TFIIH basal transcription factor.SUBCELLULAR
LOCATION: Nucleus.SIMILARITY: Belongs to the TFB4 family.
 nucleotide-excision repair/
regulation of transcription, DNA-
dependent
(P29692) Elongation factor 1-delta (EF-
1-delta)
171 3 31
EF-1-beta and EF-1-delta stimulate the exchange of GDP bound to EF-1-alpha to
GTP
 Guanyl-nucleotide exchange
factor activity/ Translation
regulator activity
(Q15024) Exosome complex exonuclease
RRP42  (Ribosomal RNA-processing
protein 42)
73 1 32
Component of the exosome 3'->5' exoribonuclease complex. Required for the 3'
processing of the 7S pre-RNA to the mature 5.8S rRNA. associated with the GTPase
Ran. Interacts directly with CSL4. Nucleus; nucleolus
DNA binding/ Cell growth and/or
maintenance
T9
gi|34335134 SEC13-like 1 isoform b 45 1 36 Molecular function unknown ( Putative nucleoporin interacting protein) unknown
T10 gi|12654583 Ribosomal protein P0 236 5 34 Localization:  Citoplasm, nucleus, nucleolus
Ribosomal subunit/ Protein
metabolism
T14
(O43684) Mitotic checkpoint protein
BUB3
137 4 38  Required for kinetochore localization of BUB1. Nucleus.
protein serine/threonine kinae
activity/Signal transduction; Cell
communication
(P68400) Casein kinase II subunit alpha 124 5 45
Casein kinases are operationally defined by their preferential utilization of acidic
proteins such as caseins as substrates. The alpha and alpha' chains contain the
catalytic site. Participates in Wnt signaling.Subunit alpha 1 e 2  interact with
HISTONE DEACETILASE 2 (HDAC2)
 Protein serine/threonine kinase
activity/ Signal transduction ; Cell
communication
(Q01085) Nucleolysin TIAR 118 3 42
RNA-binding protein. Possesses nucleolytic activity against cytotoxic lymphocyte
target cells. May be involved in apoptosis. Nuclear localization
RNA binding/Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
(Q15366) Poly(rC)-binding protein 2 84 2 39
Major cellular poly(rC)-binding protein. Binds also poly(rU). Nucleus. Cytoplasm.
Loosely bound in the nucleus. May shuttle between the nucleus and the cytoplasm
RNA binding/Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
(Q14103) Heterogeneous nuclear
ribonucleoprotein D0 (hnRNP D0)
76 3 38
Binds with high affinity to RNA molecules that contain AU-rich elements (AREs)
found within the 3-prime untranslated regions of many protooncogenes and cytokine
mRNAs. Also binds to double- and single-stranded DNA sequences in a specific
manner and functions a transcription factor. Binding of RRM1 to DNA inhibits the
formation of DNA quadruplex structure which may play a role in telomere
elongation. May be involved in translationally coupled mRNA turnover. Implicated
with other RNA-binding proteins in the cytoplasmic deadenylation/translational and
decay interplay of the FOS mRNA mediated by the major coding-region determinant
of instability (mCRD) domain. Nuclear; component of ribonucleosomes.
  Ribonucleoprotein/Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
T15
gi|1808644 arginine methyltransferase 64 2 40
Protein arginine methyltransferase that functions as a histone methyltransferase
specific for H4
Methyltransferase activity/
Histone modifing protein
gi|4758158 Septin 2 50 1 42
Septins may form a mitotic scaffold for CENP-E and other effectors to coordinate
cytokinesis with chromosome congression and segregation
Interact with S100 calcium-binding protein A4 . Nucleus.
Receptor signaling complex
scaffold activity/  Signal
transduction ; Cell communication
(O00303) Eukaryotic translation initiation
factor 3 subunit 5 (eIF-3 epsilon)
108 2 38
Binds to the 40S ribosome and promotes the binding of methionyl-tRNAi and
mRNA. Associates with the complex p170-eIF3.
 Translation regulator activity/
Protein metabolism
T16
(Q12905) Interleukin enhancer-binding
factor 2
80 3 43
Appears to function predominantly as a heterodimeric complex with ILF3. This
complex may regulate transcription of the IL2 gene during T-cell activation. It can
also promote the formation of stable DNA-dependent protein kinase holoenzyme
complexes on DNA. Nucleus; nucleolus.
  Transcription factor activity/
Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
T17
(Q86U42) Polyadenylate-binding protein
2 (Poly(A)-binding protein 2)
57 1 33
Involved in the 3'end formation of mRNA precursors (pre-mRNA) by the addition of
a poly(A) tail of 200-250 nt to the upstream cleavage product. Stimulates poly(A)
polymerase (PAPOLA) conferring processivity on the poly(A) tail elongation
reaction and controls also the poly(A) tail length. Increases the affinity of poly(A)
polymerase for RNA. Is also present at various stages of mRNA metabolism
including nucleocytoplasmic trafficking and nonsense-mediated decay (NMD) of
mRNA. Cooperates with SKIP to synergistically activate E-box-mediated
transcription through MYOD1 and may regulate the expression of muscle-specific
genes. Binds to poly(A) and to poly(G) with high affinity. May protect the poly(A)
tail from degradation.Shuttles between the nucleus and the cytoplasm but
predominantly found in the nucleus. Its nuclear import may involve the
nucleocytoplasmic transport receptor transportin and a RAN-GTP-sensitive import
mechanism. Is exported to the cytoplasm by a carrier-mediated pathway that is
independent of mRNA traffic. Nucleus; nucleoplasm; nuclear speckle.
 RNA binding/Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism/
Nuclear export/import
 (Q8NFW8) N-acylneuraminate
cytidylyltransferase
53 2 49
Catalyzes the activation of N-acetylneuraminic acid (NeuNAc) to cytidine 5'-
monophosphate N-acetylneuraminic acid (CMP-NeuNAc), a substrate required for
the addition of sialic acid. Has some activity toward NeuNAc, N-glycolylneuraminic
acid (Neu5Gc) or 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN).
Nucleus. The BC2 (basic cluster 2) motif is necessary and sufficient for the nuclear
localization and contains the catalytic active site. The localization in the nucleus is
however not required for the enzyme activity
 Ligase activity /Metabolism ;
Energy pathways
(P60842) Eukaryotic initiation factor 4A-
I
47 1 46
ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in
cap recognition and is required for mRNA binding to ribosome.  Belongs to the
DEAD box helicase family. eIF4A subfamily.
 Translation regulator activity/
Protein metabolism
T18
(P68104) Elongation factor 1-alpha 1
(EF-1-alpha-1)
245 7 50
 This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site
of ribosomes during protein biosynthesis.
Found in a nuclear export complex with XPO5, EEF1A1, Ran and aminoacylated
tRNA. Interacts with XPO5.
 Translation regulator activity/
Protein metabolism
gi|33327055 DERPC [Homo sapiens] 71 2 51
nuclear, strong basic protein; decreased expression in renal and prostate tumors; has
cell growth inhibiting function
 DNA binding/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism/ Cell
proliferation
T20
gi|8922679 smu-1 suppressor of mec-8
and unc-52 homolog
47 1 58 unknown unknown
gi|48146467  HSPC117 [Homo sapiens] 108 3 56 unknown unknown
T21
gi|5901990 katanin p60 subunit A 1
[Homo sapiens]
51 2 56
 Microtubules, polymers of alpha and beta tubulin subunits, form the mitotic spindle
of a dividing cell and help to organize membranous organelles during interphase.
Katanin is a heterodimer that consists of a 60 kDa ATPase (p60 subunit A 1) and an
80 kDa accessory protein (p80 subunit B 1). The p60 subunit acts to sever and
disassemble microtubules, while the p80 subunit targets the enzyme to the
centrosome. This gene encodes the p80 subunit. This protein is a member of the
AAA family of ATPases.
ATPase activity/Metabolism; Cell
maintenance
gi|47940653   Chaperonin containing
TCP1, subunit 8 (theta)
68 2 60
 Chaperone activity/ Cell
maintenance
gi|56789228 Chaperonin containing
TCP1, subunit 7 (eta) [Homo sapiens]
53 1 60
 Chaperone activity/ Cell
maintenanceT22
gi|71051977 HDAC2 protein [Homo
sapiens]
65 2 45
Histone deacetylase family. Deacetylase activity. Interact with  casein kinase 2, alpha
1 polypeptide
Histone modifing protein
T23
 (P14866) Heterogeneous nuclear
ribonucleoprotein L (hnRNP L)
267 11 61
This protein is a component of the heterogenous nuclear ribonucleoprotein (hnRNP)
complexes which provide the substrate for the processing events that pre-mRNAs
undergo before becoming functional, translatable mRNAs in the cytoplasm. L is
associated with most nascent transcripts including those of the landmark giant loops
of amphibian lampbrush chromosomes. Nucleus; nucleoplasm
 Ribonucleoprotein/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
 (Q13283) Ras-GTPase-activating
protein-binding protein 1 (ATP-
dependent DNA helicase V)
180 4 52
May be a regulated effector of stress granule assembly. Phosphorylation-dependent
sequence-specific endoribonuclease in vitro. Binds to the SH3 domain of Ras-
GTPase-activating protein (RASA1) in proliferating cells. No interaction in quiescent
cells.Interacts with USP10, and may regulate it. Forms homodimers and oligomers.
Cytoplasm. Cytoplasm; cytosol. Cell membrane. Nucleus. Cytoplasmic in
proliferating cells, can be recruited to the plasma membrane in exponentially
growing cells. Cytosolic and partially nuclear in resting cells. Recruited to stress
granules (SGs) upon either arsenite or high temperature treatment. Recruitment to
SGs is influenced by HRAS.
Ribonuclease activity/ Regulation
of nucleobase, nucleoside,
nucleotide and nucleic acid
metabolism
 (Q12800) Alpha-globin transcription
factor CP2 (Transcription factor LSF)
166 3 58
 Binds a variety of cellular and viral promoters including fibrinogen, alpha-globin,
SV40 and HIV-1 promoters. Activation of the alpha-globin promoter in erythroid
cells is via synergistic interaction with UBP1. Functions as part of the SSP (stage
selector protein) complex. Facilitates the interaction of the gamma-globin genes with
enhancer elements contained in the locus control region in fetal erythroid cells.
Interacts by binding to the stage selector element (SSE) in the proximal gamma-
globin promoter.
 Transcription factor activity/
Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
gi|1809248  siah binding protein 1 [Homo
sapiens]
107 2 58 Hypotetical Ribonucleoprotei/ RNA binding protein
 RNA binding/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
gi|14124984 Chaperonin containing
TCP1, subunit 3 (gamma) [Homo
sapiens]
61 1 60
 Chaperone activity/ Cell
maintenance
T24
(P33240) Cleavage stimulation factor, 64
kDa subunit (CSTF 64 kDa subunit)
324 8 61
 One of the multiple factors required for polyadenylation and 3'-end cleavage of
mammalian pre-mRNAs. This subunit is directly involved in the binding to pre-
mRNAs.Nucleus.
 RNA binding/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
gi|57209129 paraspeckle component 1 199 5 59 Putative RNA binding protein
 RNA binding/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
gi|23398584 Interferon regulatory factor
2 binding protein 1
80 1 62
 Transcription regulator activity/
Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
gi|8923040 collaborates/cooperates with
ARF (alternate reading frame) protein
74 1 61
  RNA binding/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
T25
 (Q8WXI9) Transcriptional repressor p66
beta (p66/p68) (GATA zinc finger
domain-containing protein 2)
47 1 66
Has transcriptional repressor activity. Targets MBD3 to discrete loci in the nucleus.
Nucleus. Nuclear, in discrete foci.
 Transcription regulator activity/
Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
gi|178027 alpha-actin 258 9 42 Cell maintenanceT26c
(P11940) Polyadenylate-binding protein 1
(Poly(A)-binding protein 1) (PABP 1)
48 1 71
 Binds the poly(A) tail of mRNA. May be involved in cytoplasmic regulatory
processes of mRNA metabolism. Its function in translational initiation regulation can
either be enhanced by PAIP1 or repressed by PAIP2. Can probably bind to
cytoplasmic RNA sequences other than poly(A) in vivo. May be involved in
translationally coupled mRNA turnover. Implicated with other RNA-binding proteins
in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA
mediated by the major coding-region determinant of instability (mCRD) domain.
Cytoplasm. Nucleus. Shuttles between the cytoplasm and the nucleus.
 RNA binding/Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
(Q9BTC8) Metastasis-associated protein
MTA3
58 2 68
Plays a role in maintenance of the normal epithelial architecture through the
repression of SNAI1 transcription in a histone deacetylase-dependent manner, and
thus the regulation of E-cadherin levels.Nucleus. Interact with histone deacetilase 2
non directly
 Transcription regulator activity/
Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
 (Q9UBU9) Nuclear RNA export factor 1
(Tip-associating protein)
56 1 71
Involved in the nuclear export of mRNA species bearing retroviral constitutive
transport elements (CTE) and in the export of mRNA from the nucleus to the
cytoplasm. Nuclear; localized predominantly in the nucleoplasm and at both the
nucleoplasmic and cytoplasmic faces of the nuclear pore complex. Shuttles between
the nucleus and the cytoplasm.
 RNA binding/Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
gi|57165052 Thyroid autoantigen 70kDa 53 1 70
Single stranded DNA-dependent ATP-dependent helicase. Has a role in chromosome
translocation. The DNA helicase II complex binds preferentially to fork-like ends of
double-stranded DNA in a cell cycle-dependent manner. It works in the 3'-5'
direction. Binding to DNA may be mediated by p70. Involved in DNA
nonhomologous end joining (NHEJ) required for double-strand break repair and
V(D)J recombination. The Ku p70/p86 dimer acts as regulatory subunit of the DNA-
dependent protein kinase complex DNA-PK by increasing the affinity of the catalytic
subunit PRKDC to DNA by 100-fold. The Ku p70/p86 dimer is probably involved in
stabilizing broken DNA ends and bringing them together. The assembly of the DNA-
PK complex to DNA ends is required for the NHEJ ligation step. Required for
osteocalcin gene expression
 DNA repair protein/Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
T27
 gi|15530265 Eukaryotic translation
elongation factor 1 gamma
320 8 50
 Translation regulator activity/
Protein metabolism
T28 gi|34783356 RANGAP1 protein 99 2 64
GTPase activator for the nuclear Ras-related regulatory protein Ran, converting it to
the putatively inactive GDP-bound state.
 GTPase activator activity/ Signal
transduction ; Cell communication
gi|14250668 Cortactin, isoform b 106 3 58
 Cytoskeletal protein binding/Cell
growth and/or maintenance
gi|82546879 GTP binding protein 1 106 2 73
FUNCTION: Not known, the C-terminus can act as an allosteric activator of the
cholera toxin catalytic subunit.
 GTPase activity/ Signal
transduction ; Cell communication
 (Q14157) Ubiquitin-associated protein 2-
like
97 3 104 Unclassified
 Unknown/Biological_process
unknown
 (P19447) TFIIH basal transcription
factor complex helicase XPB subunit
97 2 90
ATP-dependent 3'-5' DNA helicase, component of the core-TFIIH basal transcription
factor, involved in nucleotide excision repair (NER) of DNA and, when complexed
to CAK, in RNA transcription by RNA polymerase II. Acts by opening DNA either
around the RNA transcription start site or the DNA damage.
  DNA repair protein/ Regulation
of nucleobase, nucleoside,
nucleotide and nucleic acid
metabolism
 (Q9BSJ2) Gamma-tubulin complex
component 2
69 1 104
 Gamma-tubulin complex is necessary for microtublule nucleation at the centrosome.
Centrosome.
 Cytoskeletal protein binding/ Cell
growth and/or maintenance
T30
 (Q12906) Interleukin enhancer-binding
factor 3 (Nuclear factor of activated T-
cells 90 kDa)
64 1 96
 May facilitate double-stranded RNA-regulated gene expression at the level of post-
transcription. Can act as a translation inhibitory protein which binds to coding
sequences of acid beta-glucosidase (GCase) and other mRNAs and functions at the
initiation phase of GCase mRNA translation, probably by inhibiting its binding to
polysomes. Can regulate protein arginine N-methyltransferase 1 activity. May
regulate transcription of the IL2 gene during T-cell activation. Can promote the
formation of stable DNA-dependent protein kinase holoenzyme complexes on DNA.
Nucleus; nucleolus.
  Transcription factor
activity/Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
(Q01826) DNA-binding protein SATB1
(Special AT-rich sequence-binding
protein 1)
60 1 86
 Binds to DNA at special AT-rich sequences at nuclear matrix- or scaffold-associated
regions. Thought to recognize the sugar-phosphate structure of double-stranded
DNA. Nucleus.
 Transcription factor activity/
Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
 (P33992) DNA replication licensing
factor MCM5 (CDC46 homolog) (P1-
CDC46)
46 2 83
 DNA binding  /Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
gi|2494898 Periodic tryptophan protein 2
homolog
68 2 103
Nucleus; nucleolus. PWP2 is essential for viability and may play a role in the early
G1 phase of the cell cycle.( La prot. Possiede diversi domini WD40)
  Regulation of cell cycle/ Signal
transduction ; Cell communication
T31
(Q02779) Mitogen-activated protein
kinase kinase kinase 10
40 2 104 Activates the JUN N-terminal pathway
Protein serine-threonine kinase
activity/ Signal transduction ; Cell
communication
  (P43243) Matrin-3 160 6 95
May play a role in transcription or may interact with other nuclear matrix proteins to
form the internal fibrogranular network. In association with the SFPQ-NONO
heteromer may play a role in nuclear retention of defective RNAs. Nucleus;
nucleoplasm; nuclear matrix.
 RNA binding/Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
T32
(P11586) C-1-tetrahydrofolate synthase,
cytoplasmic (C1-THF synthase)
110 2 102 Cytoplasm
Catalytic activity/ Metabolism;
Energy pathways
(P55884) Eukaryotic translation initiation
factor 3 subunit 9
62 2 93 Binds to the 40S ribosome and promotes the binding of methionyl-tRNAi and mRNA
 Translation regulator activity/
Protein metabolism
(Q9H0D6) 5'-3' exoribonuclease 2 (EC
3.1.11.-) (DHM1-like protein)
61 1 109
Possesses 5'->3' exoribonuclease activity and may be involved in homologous
recombination and RNA metabolism, such as RNA synthesis and RNA trafficking
.Nucleus; nucleolus.
Ribonuclease activity/ Regulation
of nucleobase, nucleoside,
nucleotide and nucleic acid
metabolism
(Q99613) Eukaryotic translation initiation
factor 3 subunit 8 (eIF3 p110)
57 1 106 Binds to the 40S ribosome and promotes the binding of methionyl-tRNAi and mRNA
 Translation regulator activity/
Protein metabolism
 (Q9ULK4) CRSP complex subunit 3
(Cofactor required for Sp1 transcriptional
activation subunit 3)
102 2 158 Plays a role in transcriptional coactivation.
 Transcription regulator activity/
Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
T33
(P26640) Valyl-tRNA synthetase (EC
6.1.1.9) (Valine--tRNA ligase)
88 2 142
 Translation regulator activity/
Protein metabolism
 (Q92900) Regulator of nonsense
transcripts 1 (EC 3.6.1.-) (ATP-dependent
helicase RENT1)
70 2 126
Part of a post-splicing multiprotein complex. Involved in nonsense-mediated decay
(NMD) of mRNAs containing premature stop codons. Essential for embryonic
viability.
  RNA binding/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
 (O00267) Transcription elongation factor
SPT5 (hSPT5)
56 2 121
Component of the DRB sensitivity-inducing factor complex (DSIF complex), which
regulates mRNA processing and transcription elongation by RNA polymerase II.
DSIF positively regulates mRNA capping by stimulating the mRNA
guanylyltransferase activity of RNGTT/CAP1A. DSIF also acts cooperatively with
the negative elongation factor complex (NELF complex) to enhance transcriptional
pausing at sites proximal to the promoter. NUCLEO
transcription
 (Q13435) Splicing factor 3B subunit 2
(Spliceosome-associated protein 145)
56 1 98
Subunit of the splicing factor SF3B required for 'A' complex assembly formed by the
stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA.
Sequence independent binding of SF3A/SF3B complex upstream of the branch site is
essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the
assembly of the 'E' complex. Belongs also to the minor U12-dependent spliceosome,
which is involved in the splicing of rare class of nuclear pre-mRNA intron. Nucleus.
  RNA binding/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
 (O75533) Splicing factor 3B subunit 1
(Spliceosome-associated protein 155
52 2 146
Subunit of the splicing factor SF3B required for 'A' complex assembly formed by the
stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA.
Sequence independent binding of SF3A/SF3B complex upstream of the branch site is
essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the
assembly of the 'E' complex. Belongs also to the minor U12-dependent spliceosome,
which is involved in the splicing of rare class of nuclear pre-mRNA intron.
  RNA binding/ Regulation of
nucleobase, nucleoside, nucleotide
and nucleic acid metabolism
gi|89047296 similar to SMC hinge
domain containing 1
136 3 221 Unknown
T34
gi|33946327 nucleoporin 214kDa [Homo
sapiens]
54 3 214 integral to membrane.Interact with  con Nuclear RNA export factor 1
porin activity/ protein import/
export
gi|71044479  death inducer-obliterator 1
isoform c
358 12 245
Apoptosis, a major form of cell death, is an efficient mechanism for eliminating
unwanted cells and is of central importance for development and homeostasis in
metazoan animals. In mice, the death inducer-obliterator-1 gene is upregulated by
apoptotic signals and encodes a cytoplasmic protein that translocates to the nucleus
upon apoptotic signal activation. When overexpressed, the mouse protein induced
apoptosis in cell lines growing in vitro. This gene is similar to the mouse gene and
therefore is thought to be involved in apoptosis. Alternatively spliced transcripts have
been found for this gene, encoding multiple isoforms.
 Putative DNA binding protein/
Cell proliferation/ Apoptosis/
Regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolism
T35
gi|13606056 DNA dependent protein
kinase catalytic subunit [Homo sapiens]
106 4 470
Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage.
Involved in DNA nonhomologous end joining (NHEJ) required for double-strand
break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its
catalytic properties. Promotes processing of hairpin DNA structures in V(D)J
recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The
assembly of the DNA-PK complex at DNA ends is also required for the NHEJ
ligation step. Required to protect and align broken ends of DNA. May also act as a
scaffold protein to aid the localization of DNA repair proteins to the site of damage.
Found at the ends of chromosomes, suggesting a further role in the maintenance of
telomeric stability and the prevention of chromosomal end fusion. Also involved in
modulation of transcription. Recognizes the substrate consensus sequence [S/T-Q].
Phosphorylates Ser-139 of histone variant H2AX/H2AFX, thereby regulating DNA
damage response mechanism.
protein kinase  activity/DNA
REPAIR
